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ABSTRACT 
Francisella tularensis is one of a small group of bacteria recognized for their virulence 
and potential for use as biological weapons. In this study we utilize a novel approach to identify 
an immunologically prominent component of F. tularensis that appears to be a promising 
vaccine candidate. Francisella is an intracellular pathogen that infects cells of the 
reticuloendothelial system. Other bacteria, such as Brucella spp. have this part of their life 
cycle in common. However, while mice injected with F. tularensis all die within three weeks 
of infection, mice injected with Brucella spp. survive and produce antibodies to the bacteria 
which are immunologically reactive not only with Brucella spp. but, also with Francisella. 
When we vaccinated mice with a B. abortis O-linked polysaccharide (OPS) and then 
challenged them with 10 LD 5 0 F. tularensis LVS, 60% survived. Sera from Brucella OPS-
primed / F. tularensis-challenged mice was used to identify immune reactive proteins from F. 
tularensis. A novel 52 kDa fraction was identified. While vaccination of mice with this 
partially purified fraction only provided 20% protection to F. tularensis challenged mice, both 
whole cell extracts and a partially purified soluble fraction (>30 kDa) given to Brucella-
vaccinated mice were 100% protective. The 52 kDa enriched fraction elicited a rudimentary 
cytokine burst of nitric oxide in a cell culture of J774.1 macrophages. The 52 kDa fraction was 
degraded by proteinase K and appeared to decrease in size to 36 kDa in the presence of 
DNAase, suggesting a possible protein and nucleic acid composition. The host response to F. 
tularensiss infection is complex, but given the ability of the 52 kDa component to protect 
iii 
against live vaccine challenge, and its apparent ability to elicit a cytokine burst, this component 
may have potential use in future vaccine production. 
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1.0 Introduction 
In 1970, the World Health Organization (WHO group of consultants, 1970) identified 
Yersinia pestis, Bacillus anthracis, and Francisella tularensis, the causative agents of 
plague, Anthrax and Tularemia, respectively, as bacterial candidates most likely to be used as 
biological warfare weapons. Following September 11, 2001 whereby American civilian targets 
were exposed, infected, and in some cases died from Anthrax, the biological threat has become 
very real and very near. Although the focus of public concern has been on Anthrax, it should 
be noted that it takes about 5,000 to 12,000 spores of Bacillus anthracis to cause human 
infection (DIA, 1986), whereas only 1 to 10 cells of F. tularensiss are needed to cause 
Tularemia (Cross, et al, 2000). This high virulence alone makes F. tularensiss a likely 
organism to be used as a weapon of terror. 
F. tularensiss can be readily grown on agar or in broth culture medium, harvested, and 
disseminated. Within a human host, its incubation period can range from one to 14 days 
(Dennis, et al, 2001). Once infected into a population, it may confound primary care 
physicians who may struggle to identify the unusual agent causing severe "flu-like" symptoms 
which can be associated with a high rate of morbidity and mortality. A covert attack on a 
population would require enhanced epidemiological skills of primary care physicians to 
investigate and correctly identify potentially rare, or unusual disease causing organisms 
(Christopher, et al., 1997). While response to late diagnosis can be aggressive antibiotic 
therapy, these treatments are not always given in time to cure infected individuals. It is because 
of this fact that F. tularensis is listed high on threat lists of biological weapons by committees 
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and countries around the world (The Biological and Toxins Weapons Convention, Geneva, 
Switzerland, 1971 to present). 
A key element for defense against use of F. tularensis as a bioterrorist weapon is 
access to an effective and safe vaccine. Unfortunately, the only available vaccine to Tularemia 
has recently been suspended. In the following study, a vaccine candidate for F. tularensis is 
successfully identified. Our production technique and assays describing the composition and 
activities of the component identified are described. A description of the discovery and 
significance of Tularemia, where it is found, the bacterium and its infection into humans, 
methods of detection, treatment and research towards finding a suitable vaccine are described. 
Although much has been accomplished, there is much more to do and it is hoped that the novel 
approaches identified in this work will assist the scientific community in developing new 
measures counteracting the bioterrorist threat. 
1.1 Discovery of Francisella tularensis 
In the early portion of the 20* century, various researchers described a small bacterium 
that caused a plague-like disease in rodents. George McCoy, a physician in the Tulare County 
of California, first described the disease in detail (McCoy and Chapin, 1912a and 1912b). At 
this time, the agent became known as Bacterium tularense. Shortly after, Edward Francis 
described the same disease in humans and labeled the collection of symptoms Tularemia. He 
suggested that insect vectors were responsible for transmission of the disease between rodents 
and humans (Francis, 1921) and was able to successfully isolate the organism from serum. 
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Francis himself was infected with F. tularensis three times and eventually died from Tularemia 
(Tarnvik, et al, 1997). The bacterium eventually was named in his honor. 
A disease similar to Tularemia also was described in Japan by Ohara (Ohara, 1926). 
Ohara infected his wife and was able to recover an organism similar to F. tularensis from a 
dissected lymph node, a clear demonstration of Koch's postulates. Francis later confirmed the 
identity of Ohara's plague-like disease organism as F. tularensis (Francis and Moore, 1926). 
1.2 Significance of Tularemia 
While worldwide prevalence of Tularemia is decreasing, it is still an important pathogen 
in some regions. The number of reported cases of Tularemia in the United States in 1994 
totaled 96 (Koo, et al. 1994). In Japan, the incidence of Tularemia peaked in the two decades 
following World War II (Ohara, et al, 1996) with a total of 1372 cases being reported since 
1924. A large proportion (93%) of the cases in Japan resulted from infection of persons 
handling diseased rabbits; few cases were the result of tick bites. In Sweden, over five 
thousand cases have been reported throughout the past seventy years (Tarnvik, et al, 1996). 
Many of these cases have been linked to a cycling population of voles. Because F. tularensis 
can persist in cold water for months at a time without losing its ability to infect host organisms, 
it poses a concern in colder climates. In south western Canada, a recent survey showed that 
antibodies to F. tularensis can be detected in serum collected from rural dogs and cats, 
indicating that the bacterium is present in the wild and is a potential threat to humans (Leighton, 
et al, 2001). 
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1.3 Epidemiology and Taxonomy of Tularemia 
F. tularensiss primarily is distributed throughout the northern hemisphere. Cases have 
been reported in Japan, Russia, Sweden, Spain and the United States (Ohara, et al, 1996; 
Tarnvik, et al, 1996). Its distribution across continents has resulted in further classification of 
the species into subspecies tularensis and palaearctica, which are distributed mainly into 
North America and Eurasia, respectively (Olsufiev, et al, 1959). F. tularensiss biovar 
tularensis is also classified as Jellison Type A, whereas biovar palaearctica is classified as 
Jellison Type B. This classification was done to describe differences in virulence and natural 
reservoirs of the disease. The North American F. tularensis biovar tularensis is more 
prevalent worldwide. This biovar is highly virulent to mammals and most commonly infects 
lagomorphs (rabbits and hares). Other natural hosts include various rodents (voles, squirrels, 
muskrats, beavers) and arthropods (Cross and Penn, 2000). In North America, a common 
mode of transmission to humans is via ticks (Jellison, et al, 1974) such as the common wood 
tick, Demacentor andersoni (Cross and Penn, 2000). Handling of infected animals can lead 
to infection. Infection with F. tularensis biovar tularensis is associated with a 5% mortality 
(Doan-Wiggins, 1991). F. tularensis biovar palaearctica is found mainly in Asia and Europe. 
This bacterium is lower in virulence than the North American strain but, in addition to being 
isolated from rabbits, it also has been found in water (Jellison, 1974) and can be easily 
aerosolized (Dennis, et al, 2001), making it a potentially dangerous bioweapon. Current live 
vaccine protocols for Tularemia have been developed using attenuated F. tularensis biovar 
palaearctica. 
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In addition to biovars tularensis and palaearctica, F. tularensis biovar novicida and 
the separate species, F. philomiragia also have been identified (Forsman, et al, 1994). Both 
have low virulence for mammals as well as a different cellular morphology than F. tularensis 
biovar tularensis but are linked to the genus Francisella by similarities in their genetic code. F. 
tularensis biovar novicida has only been successfully recovered from a Utah Water source 
(Larson et al. 1955). Based on 16S RNA sequencing, F. tularensis appears to be closely 
related to a number of water-borne bacteria such as Piscirickettsia, Cycloclasticus and 
Caedibacter (Titball, et al, 2003). In terms of human pathogens, the most closely related 
organisms were Coxiella burnetti and Legionella spp. 
1.4 Microbiology and Virulence Factors of Francisella tularensis 
F. tularensiss, the causative agent of Tularemia, is a Gram-negative, rod-shaped 
bacterium measuring 0.2 x 0.7 pim (Eigelsbach and McGann, 1984; Saslaw, et al, 1961). It is 
a nonmotile, obligate aerobe. Culture requirements for Francisella are more stringent than for 
other bacteria. It is a slow growing bacterium and successful culture of the organism often 
requires glucose-cysteine agar (GCA) with thiamine or cystine heart agar, but peptone cystine 
broth and a chemically defined medium also have been used (Chamberlain, 1965). Small, gray 
colonies surrounded by a green zone of discoloration are typically produced after 2-3 days of 
growth on GCA. The double membrane of F. tularensis has a high lipid content (50-70%) 
and contains a large fraction of saturated C20 to C26 fatty acids (Hood, 1977; Eigelsbach and 
McGann, 1984). F. tularensiss is capable of producing human disease with transmission of as 
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little as 10 organisms (Cross and Penn, 2000). As a result, extreme caution is required in the 
laboratory, often requiring biohazard level three protocols. 
The capsule of F. tularensis is thought to be a requirement for virulence. Hood (1977) 
discovered that loss of virulence was associated with loss of the capsule. However, 
Cherwonogrodzky et al. (1994) observed that culture of an avirulent strain of F. tularensis on 
synthetic medium allowed the bacteria to regain virulence. Carbohydrates present in the 
capsule appear to be antigenic and responsible for imparting humoral immunity in vaccinated 
individuals (Tarnvik, 1989) while cell surface proteins are thought to be responsible for 
conferring long-term cellular immunity. The role of carbohydrates and cell surface proteins in 
the pathogenesis of F. tularensis infection has not been thoroughly investigated. 
Recently, some novel research has investigated the apparent lack of hemolytic activity 
possessed by F. tularensis. Lai et al. (2003) discovered that F. novicida produces a 
hemolysin, defined as novilysin. They proved, through solid and liquid culture assays, that F. 
novicida produces a hemolysin of fairly low activity. However, novilysin was only identified in 
F. novicida, not F. tularensis, indicating the need for further research in this area. Moreover, 
this novilysin cross reacts with E. coli hemolysin HlyA. The same research group identified 
homology between the F. tularensis acid phosphatase A (AcpA) and a Pseudomonas 
aeruginosa hemolytic phospholipase C. The homology between Francisella and other 
pathogenic organisms suggests that there is a great deal of cross reactivity between seemingly 
distant organisms. Also, it does not preclude the sharing of similar virulence factors amongst 
seemingly dissimilar organisms. If hemolysin is common and cross reactive with both 
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Francisella and Eschericia, there may be similarities with other virulence determinants. 
Francisella appears to contain within its cellular machinery components which are similar, but 
in low activity, to other organisms. It may be possible to protect a host against Francisella 
challenge by infecting it with a similar, but related organism. 
1.5 The infection and host responses 
Tularemia can classically cause a cluster of six different clinical manifestations: 
ulceroglandular, glandular, oculoglandular, oropharyngeal, typhoidal and pneumonic disease 
(Evans et al, 1985; Cross and Penn, 2000). Fever and lymphadenopathy are features 
common to most infections. While the host incubation period for infection averages 3 to 5 days, 
it can range from 1 to 14 days and extend up to 21 days (Sanders and Hahn, 1968). 
Ulceroglandular disease is found in up to 80% of clinical situations and is usually the 
result of tick bites, animal bites or handling of infected carcases. An ulcer typically forms at the 
site of initial infection and eventually progresses to form a black eschar. Tender 
lymphadenopathy in the region draining the infection site occurs with this type of infection. 
Often, the instigating organism can be cultured from a lymph node aspirate or biopsy (Ohara, 
1926). Glandular disease occurs with the absence of a cutaneous lesion, but requires the 
presence of infected lymph nodes. Oculoglandular disease is often the result of the patient 
inoculating the conjunctiva with contaminated digits. Conjunctivitis with preauricular 
lymphadenopathy and periorbital edema is a feature of this type of infection. Oropharyngeal 
Tularemia occurs with ingestion of contaminated substances (Jansen, et al, 2003). An 
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exudative pharyngitis and cervical lymphadenopathy is usually present which may progress to 
ulceration of the oropharynx. Typhoidal Tularemia is a systemic form of the disease. The 
patient appears toxic and may exhibit septic shock. Significant outcomes may include 
rhabdomyolysis, disseminated intravascular coagulopathy and secondary renal failure. The 
pneumonic form of the disease can occur from hematologic spread from a distant infection site, 
or from inhalation of vegetative cells. Tularemic pneumonia, a true colonization of the lungs, 
presents with a triad of ovoid opacities, pleural effusions and hilar adenopathy (Choi, 2002) and 
should be considered when a community acquired pulmonary infection does not respond well to 
conventional P-lactam antibiotics. 
1.6 Identification of Francisella tularensis 
Diagnosis of F. tularensis infection is difficult for investigators. The organism is difficult 
to culture from blood and requires special media supplemented with cysteine to grow. The 
danger of aerosolization is a constant hazard to laboratory workers (Shapiro, et al, 2002) as 
during the initial plating procedure, the organism can be confused for a Haemophilus species. 
Both laboratory personnel as well as pathology staff are in danger of exposure, since 
Harmophilus is routinely handled in a Level 1, or benchtop, environment. Francisella, when 
identified, requires the use of a BioSafety cabinet and a Level 2 work environment. 
Regardless, current protocols using serum agglutination tests indicate that a single titre greater 
than 1:160 or a four-fold rise in serum titre is indicative of F. tularensis infection (Evans, et al., 
1985). Often obtaining a detailed history to ascertain exposure to the organism and a low 
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threshold of suspicion is necessary to facilitate accurate diagnosis. 
Grunow, et al. (2000) were successful in developing environmental detection systems 
for F. tularensis. These systems use either PGR, targeting sequences of the 17 kDa TUL4 
gene, or ELISA using monoclonal antibodies. The systems are capable of detecting between 
102 and 10 4 bacteria/mL of serum. Highly specific detection systems, such as these, are 
powerful tools in the early and rapid detection of Francisella in both the environment and in 
human patients. 
1.7 Methods for treating Tularemia 
Diagnosis and treatment of F. tularensis can be difficult. The bacterium is classified as 
an intracellular pathogen because of its ability to reside within host cells. Because of this 
property, choice of antibiotics is limited. The current antibiotic of choice is streptomycin 
(Enderlin, et al, 1994), but gentamicin, tetracycline and chloramphenicol can be used as 
alternatives. Streptomycin has the best cure rate with few relapses, whereas gentamicin and the 
other aminoglycosides have been shown to have poor bioavailability for intracellular pathogens 
and abscesses. Fluoroquinolones, such as ciprofloxacin and levofloxacin, also have been used 
with some success. Cephalosporins are a poor choice of antibiotic and have resulted in 
therapeutic failures (Choi, 2002). 
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1.8 Immune Modulation - Vaccine development 
The intracellular nature of Tularemia has challenged scientists in creating a safe, and 
effective vaccine. In the disease process, the bacterium invades macrophages and epithelioid 
cells (Cross and Penn, 2000). Often the liver and spleen are the first organs targeted (Conlan, 
et al., 2003). Unless respiratory inoculation took place, the lungs are colonized after the 
reticuloendothelial system. An immune response is elicited and granulomas are formed. 
Humoral immunity develops towards carbohydrate elements of the bacterium, but this is not 
sufficient to clear the disease. Cell-mediated immunity, utilizing a T-cell response against surface 
antigens, is necessary to cure the host (Tarnvik, 1989). Once the host is cured, it is thought that 
immunity is sufficient for a lifetime of protection against Tularemia, although examples to the 
contrary are present. 
Current vaccine protocols utilize a live vaccine strain (LVS) developed from F. 
tularensiss biovar palaearctica from Russia. This LVS lacks a sufficient cell coat, or capsule, 
to protect itself from host defenses. A low-grade infection of F. tularensis results from LVS 
administration and sufficient cell-mediated immunity to protect the host is elicited. While it is 
thought that cell surface components are necessary for imparting long-term immunity, the exact 
role of T-cells and B-cells for protection against F. tularensis has not be fully explored. 
The intracellular, parasitic nature of F. tularensis, and host response to this infection, 
has been the focus of recent research in this area. Hood (1977) and Skrodzki (1968) have 
suggested that toxic components of F. tularensis differ from those of Salmonella and Shigella, 
which are often of the classical two-part toxin class of protein toxins. Their research indicates 
10 
that toxic components from F. tularensis possess very little toxicity and are thermolabile 
(Skrodzki, 1968). Contemporary research has so far been unsuccessful in isolating a specific 
virulence factor which explains the rather high lethality of F. tularensiss. 
Further work by Sandstrom et al. (1992) has shown that the lipopolysaccharide (LPS) 
classical endotoxin component of F. tulatensis LVS, which is analogous to the endotoxins from 
other gram negative bacteria such as Eschericia coli, possesses very little toxicity. LPS from 
F. tularensis LVS failed to stimulate lymphocytes in primed individuals, had no lethal activity in 
galactosamine-sensitized (LPS sensitive) mice and failed to activate the Limulus amoebocyte 
lysate assay for LPS (Sandstrom et al., 1992). It does not act as a pyrogen (Guss, 1970) and 
is 1000 times less lethal than LPS from Escherichia coli. LPS from F. tularensis LVS does 
not induce tumor necrosis factor alpha or nitric oxide in animal cells (Ancuta, et al, 1996). In 
some pathogen/host model systems, it has been suggested that LPS modulates humoral 
immunity, triggering the production of antibodies in infected individuals. However, for F. 
tularensis, components other than the LPS appear necessary for the production of the cellular 
immunity which eventually clears the host of infection. 
In a comparison between high and low-virulence strains of F. tularensis, investigators 
determined that immunization with LPS from F. tularensis LVS did not provide adequate 
protection against challenge from a highly virulent strain (Fulop, et al., 2001). However, LPS 
and F. tularensis LVS in combination did protect against the high virulence strain. This 
protection was abolished when CD4+ and CD8+ cells were removed, indicating, once again, 
that a cell-mediated process is required for development of an immune response to infection 
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and that cellular components are necessary for this immunity. The authors suggest that other 
antigens, in addition to LPS, are required in the development of a successful vaccine for virulent 
F. tularensis. 
The host immune response to F. tularensis infection is an interesting one. Lai et al. 
(2001) suggest, from work completed with J774.A1 murine macrophages, that colonization of 
these macrophages results in apoptosis. The host response of programmed cell death to 
infection may be a protective measure to expose the bacterium to a less hospitable 
environment, a mechanism that would specifically target intracellular pathogens such as 
Francisella (Kaufmann, 1999). Once within the intracellular environment, F. tularensis 
appears to possess a mechanism to counter the destructive effects of the 
polymorphoneutrophils (PNMs). Reilly et al. (1996) characterized a novel acid phosphatase 
(AcpA) from F. tularensis, which suppresses the respiratory burst from PMNs. This AcpA 
was recovered both from cell lysates and from cell culture medium. It had an activity greater 
than any other acid phosphatase purified, at that time and appeared to be able to hydrolyze 
neutrophil-surface components responsible for triggering the respiratory burst associated with 
apoptosis (Reilly, et al., 1996). 
Mounting of an immune response to intracellular pathogens is a complex task. The 
cellular immunity, that is a requirement for long-term protection against intracellular pathogens, 
such as F. tularensis, is based on T-cells, B-cells and Natural Killer (NK) cells. Cytokines 
produced, such as Interferon Gamma (IFN-y), tumor necrosis factor alpha (TNF-a) and nitric 
oxide (NO) serve as messengers between these immune components. Intraperitoneal (IP) and 
12 
intranasal (IN) injections of F. tularensis have an LD 5 0 approaching a single organism, in a 
susceptible murine line such as BALB/cByJ (Fortier, et al., 1991), making mice a good in vivo 
model for studying the immune response to infection. 
There have been a number of in vivo studies investigating the role of cellular and 
humoral immunity, in the form of T-cells and B-cells, and cytokines in controlling and clearing 
Francisella infection. It has been observed that mice lacking mature T-cells (nu/nu athymic 
mutant) can partially control infection, but ultimately succumb thus demonstrating the 
requirement of T-cells for long term protection. Studies using IFN-y deficient mice indicate that 
this component is necessary for initial defense against Francisella (Elkins, et al, 1996). 
Further research implicates the requirement of functioning B-cells for defense (Dreisbach, et 
al, 2000). Interestingly, exposure to F. tularensis LVS LPS was insufficient to upregulate 
IFN-y and activate B-cells. Using B-cell deficient mice (BKO), Culkin et al. (1997) 
demonstrated the requirement of functioning B-cells for protection against secondary F. 
tularensis infection. Successful clearance of F. tularensis from a host confers long-term 
protection. In BKO mice, primary infection with the organism was successful, but long term 
protection was absent. Measurements of the cytokines IFN-y and NO were similar in both 
BKO and native mice, suggesting that primary clearance of the pathogen is required for 
induction of long term immunity. The results from this experiment with BKO mice suggest a role 
for B-cells in long-term protection against intracellular pathogens. The B-cell arm of the immune 
system may be responsible for T-cell priming (Bosio, et al, 2001) and regulation of the T-cell 
response to F. tularensis. It appears that the host response to intracellular colonization with F. 
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tularensis is a complex process. 
The role that antibodies play in the protection against intracellular pathogens is 
somewhat controversial. Recently, it has been shown that humoral immunity does play a role in 
protecting against such organisms as Ehrlichia, Salmonella, Mycobacterium, Legionella, 
Brucella and Richettsia (Winslow, et al, 2000). Both antibody and cellular responses are 
required to suppress and clear infection. With commonalities being shared amongst bacteria, 
this observation is applicable to our own research. The elicitation of an antibody response 
surely is part of the key to the development of a successful vaccine for Francisella. 
Subcellular vaccines are preferred over live vaccines because of the ease of quality 
control and 'cleanliness' of preparation. However, subcellular vaccines have so far been 
ineffective for Tularemia because they elicit only a humoral response. However, some 
subcellular components are respectable T-cell mediators. Carbohydrates present in the capsule 
appear to be antigenic and responsible for imparting humoral immunity in vaccinated individuals 
(Tarnvik, 1989) while cell surface proteins are thought to be responsible for conferring long-
term cellular immunity. Requirement for development of a cell-mediated immune response, 
coupled with the need for the development of humoral immunity has presented a significant 
challenge to the creation of a vaccine for F. tularensis. 
With knowledge that LPS from F. tularensis, by itself, is ineffective in conferring 
long-term immunity to infection, there has been a move in the research community to 
characterize proteins from Francisella with the intention that these proteins be used as 
subcellular vaccines. It is thought that proteins exposed to the host immune system might be 
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key in this development. As a result, researchers have focused their efforts on identifying and 
characterizing immunologically significant proteins obtained from the organism. 
Early work identified membrane polypeptides that could be recognized by T-cells from 
individuals that had recovered from F. tularensis infection (Sjostedt, et al, 1990). T-cell 
induction did not occur in individuals not exposed to F. tularensis. A 17-kilodalton (kDa) 
T-cell stimulating protein was soon identified and denoted TUL4 (Sjostedt, et al, 1991). 
TUL4 protein is a lipoprotein observed in Western blots utilizing serum from F. tularensis 
exposed individuals and has been used to develop a hand-held device for the early detection of 
F. tularensis (Grunow, et al, 2000). 
A 23 kDa protein was identified by comparing F. tularensis grown in liquid 
Chamberlain medium to F. tularensis grown in the intracellular environment of murine J774.1 
cells (Golovliov, et al, 1997). This protein appeared necessary for growth in the macrophage 
intracellular environment. Other proteins have been identified by comparison of the live 
vaccine strain to wild-type stains of F. tularensis using two-dimensional gel electrophoresis 
(Hernychova, et al, 2001); these include a DNAK heat shock protein 70 (73.6 kDa), GroEL 
(56.7 kDa), acid phosphatase (56.1 kDa) and a 23 kDa protein. These proteins were all 
present in wild-type strains of the organism. Using serum from F. tularensis exposed 
individuals, immunoreactive proteins also were identified (Havlasova, et al, 2002). While 
many proteins were immunoreactive, the TUL4 lipoprotein (17 kDa), a 60 kDa chaparonin, the 
DNAK chaparonin, a 10 kDa chaparonin and the 23 kDa protein were most notable. These 
proteins were not detected with serum obtained from subjects not exposed to Francisella. 
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Over the past 3-4 years, there has been a thrust in research to map immunoreactive 
proteins. One group has undertaken 2D gel electrophoresis to compare serum from unexposed 
individuals (naive) to that of Tularemia survivors with the intention of identifying immunologically 
active components. Havlasova et al. (2002) was successful in identifying 22 components by 
mass spectrophotometric analysis. The group identified the 17 kDa TUL4 protein (Sjostedt et 
al, 1991) that has since been incorporated into a handheld immunochromatrographic assay 
(Grunow et al, 2000). A chaperonin protein with a molecular weight of 60 kDa was also 
identified (CPN60) which appears in other pathogenic bacteria such as Legionella 
pneumophilia, Pseudomonas aeruginosa and Clostridium difficile. This apparent cross 
reactivity to a protein thought to be responsible for adherence is part of the basis for our work 
presented. We hope to demonstrate that an immune response to a single organism, such as 
Francisella, may provide a level of protection against other organisms. Similarly, defense 
against a broad group of organisms, for example the gram negative pathogens, may provide a 
base level of protection against a rare, but pathogenic member of that particular class. As such, 
the cross reactivity between Francisella and Brucella is the basis of our identification of an 
immunologically reactive component to F. tularensiss. 
The genome of F. tularensis strain Schu-S4 has been published and is rapidly 
becoming a powerful tool in the analysis of the intracellular bacterium (Prior et al, 2001). 
Identified within the genome were a large number of open reading frames (1804) with the 
current identification of only 124 proteins (Hubalek et al, 2003). These proteins were 
identified by 2D gel electrophoresis and time-of-flight mass spectromometry. There were 
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numerous proteins identified within the 50 kDa molecular weight range with homology to such 
bacterium as Salmonella typhimurium, Clostridium symbiosum, Vibrio cholerae and 
Borrelia burgdorferi. Previous researchers had identified the 10 kDa chaperonin, the 17 kDa 
TUL4 and the 60 kDa chaperonin as being immunologically active (Havlasova, et al, 2002). 
The 60 kDa chaperonin protein (Accession No.P94798) is identified strongly with serum from 
F. tularensis survivors. 
Previous work has documented the cross-reactivity between Brucella spp. and 
Francisella spp. (Francis, 1926). In agglutination studies, this cross-reactivity has ranged from 
23 to 32% in specimens collected from volunteers previously infected with Francisella or 
Brucella (Behan, et al., 1982). Like Francisella, Brucella is an intracellular pathogen that 
infects the reticuloendothelial system. However, unlike Tularemia, Brucellosis can manifest as a 
subacute, or dormant, disease. Successful clearance of infection is thought to be due to 
immunity directed towards the LPS (Montaraz, et al., 1986). The polysaccharide components 
necessary for successful clearance have been extracted and incorporated into a subcellular 
vaccine that is useful in protecting against Brucella. Moreover, specific moieties present in the 
Brucella polysaccharide are shared amongst other pathogenic bacteria, such as Escherichia 
coli 0157:H7, Salmonella godesburg and Pseudomonas maltophilia 555. This knowledge 
of cross-reactivity between Francisella spp. and Brucella spp., coupled with the observation 
that successful clearance of Brucella is due to antibodies directed towards surface antigens 
such as LPS formed the basis for our current research model. 
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1.9 Using Brucella immunized mice to identify Francisella components 
We hypothesize that immunologically significant proteins, with potential vaccine or 
industrial use, can be identified using sera from mice that have naturally, and successfully 
cleared infection. 
In this study we utilize a novel approach to identify immunologically significant 
components to F. tularensis. Normally, mice injected with F. tularensis die before immune 
sera can be recovered. A group of Francisella sensitive mice were immunized with a novel B. 
abortus OPS vaccine and, after immunization, these mice were challenged with F. tularensis 
LVS. Surviving mice were used to recover sera with antibodies directed against cell surface 
components from F. tularensis LVS. These antibodies were used to identify immunologically 
significant proteins with potential for use as a vaccine for F. tularensis. Cell surface 
components characterized then, were tested for their ability to protect unimmunized mice 
against F. tularensis LVS challenge. 
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2.0 Materials and methods 
2.1 Bacterial Cultures and Growth 
A stock culture of F. tularensiss live vaccine strain (LVS) was acquired as a freeze-
dried experimental vaccine (Lot #11, Code Number: NDBR 101, 2.4 X 109 colony forming 
units per ml when rehydrated) from the United States Army Medical Research Institute of 
Infectious Diseases (USAMRIID), Frederick, Maryland, USA. 
Brucella abortus strain 30 was acquired from the Animal Diseases Research Institute -
Nepean, (ADRI-Nepean) Ontario. Growth was maintained on Brucella agar (Merck Frosst 
Chemicals, Canada) with 1.5 ppm crystal violet incubated as for F. tularensis LVS. Five-
percent phenol-killed B. abortus 1119-3 was acquired from Dr. Janet Payeur, United States 
Department of Agriculture (USDA), Ames, Iowa. This was the source for O-polysaccharide 
vaccine, which was purified by a method previously described (Lord, et al, 1998). 
Staphylococcus aureus ATCC 25923 was obtained from Fisher Scientific (Ottawa, 
Bactrol Discs Set A), Escherichia coli 0157:H7, Salmonella godesburg and Pseudomonas 
maltophilia 555 were obtained from Dr. Douglas Griffith (NRC, Ottawa). 
F. tularensis LVS was grown using a synthetically defined medium as described by 
Chamberlain (1965) (appendix B). Chamberlain's synthetic medium (CSM) was used for all F. 
tularensis LVS growth experiments. F. tularensiss was grown either on agar or in broth 
synthetic media at 37°C, 90% humidity and 5% C 0 2 . Broth cultures were grown in a rotating 
shaking incubator set at 125 rotations per minute. Agar cultures were maintained at the 
conditions specified in an incubator. A single vial of stock culture was used to inoculate 10 ml 
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peptone-cysteine broth tubes. These were incubated for 48h until the culture possessed an 
opaque blue appearance when illuminated with incident light. These were added to 500 mL 
CSM base in 1 L sterile flasks then incubated as described until early logarithmic or late 
stationary phase, depending on requirements. The absorbance of the liquid culture was 
measured at 600nm and recorded. 
F. tularensis LVS was subcultured by transferring 5 mL bacterial suspension into 500 
mL pre-warmed sterile CSM. Agar plates were created by preparing a double strength solution 
of CSM and adding it to 4% agar (Difco, Detroit Mich., USA). Staphylococcus aureus 
ATCC 25923, Escherichia coli 0157:H7, Salmonella godesburg and Pseudomonas 
maltophilia 555 were grown in Luria Broth consisting of: 10 g/L Bacto-peptone, 5 g/L Bacto 
yeast extract (Sigma Chemicals, St. Louis, Minn., USA) and 10 g/L sodium chloride all set to a 
pH of 7.4. These cultures were incubated, centrifuged and sonicated as noted for LVS in this 
section. 
Prior to infection of subject mice, F. tularensis LVS (10 LD 5 0 is equal to 1 X 10 5 
cells) was diluted in pre-warmed PBS (phosphate buffered saline). Intranasal inoculations were 
completed with 0.01 mL delivered to a single nostril of each anaesthetized mouse. 
Intraperitoneal injections were completed with an injection of 0.1 mL (10 L D 5 0 is equal to 1 X 
10 6 cells). Saline without phosphate was found to decrease the virulence of the bacterium. 
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2.2 Preparation of bacterial products 
To protect against aerosolization, all sonications were completed within a Biosafety 
Cabinet under Level 2 Biological safety conditions. Bacterial cultures were sonicated following 
centrifugation (10,000 x g, 4°C, 30 min). The cell product pellet was resuspended in sterile 
PBS and stored at -70°C until used. A Soniprep 15 and a Process Timer (MSE™) was used 
to prepare sonicated bacterial products. Cellular suspensions of the pellet returned following 
centrifugation were cooled at 4°C during sonication. The amplitude of the 10 mm probe was 
adjusted manually to 10 um. The sequence of sonication was 5 cycles of 15 seconds of pulses 
with 1 minute rest between cycles. Staphylococcus aureus ATCC 25923, E. coli 0157:H7, 
S. godesburg and P. maltophilia 555 were centrifuged (10,000 x g, 4°C, 30 min) and the 
pellet suspended in 25 mL sterile PBS (22°C). A sequence of sonication of 5 cycles of 15 
seconds, with one minute rest between cycles, was performed for each bacterial sample. The 
disrupted cell suspension was centrifuged (10,000 x g, 30 minutes) and the supernatant 
removed. Sodium azide was added to a final concentration of 0.1 % prior to storage at 4°C. 
The disrupted cellular components following sonification were separated from unbroken 
cells or cell debris by centrifugation at 10,000 x g, 4°C for 30 min. The supernatant was 
decanted and stored. This stored material, free of debris and cells, was dialyzed with a 
Spectrapor 10,000 molecular weight (MW) cutoff dialysis bag against ImM HEPES and 1 
mM DTT (dithiothreitol) for 24 hours. The dialysis was then repeated twice more against 
water for 24 hours each and stored at 4°C. The azide-fixed prepared cell-free cell lysates of F. 
tularensiss LVS, Staphylococcus aureus ATCC 25923, E. coli 0157:H7, S. godesburg and 
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P. maltophilia 555 was then utilized in experiments requiring disrupted cell lysate. 
Cell-free, sterile supernatants of F. tularensis LVS were required. Following growth 
in liquid defined media, as described before, cultures were centrifuged (10,000 x g, 4°C, 30 
min). The supernatant was decanted and filter-sterilized through a 0.22 urn filter sterilizing flask 
(Nalgene). The sterile filtrate, defined F. tularensiss LVS supernatant, was stored at 4°C until 
needed. 
F. tularensiss LVS supernatant preparations were concentrated with an Amicon 
ultrafiltration system pressurized to 55psi with dry nitrogen utilizing a 30 kDa MW cutoff 
membrane (MWCO) (Millipore Co. Nepean, ON). The retentate, containing components 
larger than 30 kDa, was stored at 4°C. Several supernatants from the Amicon ultrafiltration 
procedure were further concentrated in Amicon 30 kDa MWCO Centriprep YM-30 
centrifugal filter device (Millipore Co. Nepean, ON) centrifuged at 1,000 x g for 60 min. 
Retentate was collected and stored at 4°C until required. 
Several flasks of F.tularensis LVS were grown in CSM as described, and 
subsequently filter sterilized (0.20um, Nalgene). The resultant F .tularensis LVS supernatants 
were then frozen at -70°C and lyophilized. The dry samples were stored in air-tight containers 
at 22°C until required. 
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2.3 Polyacrylamide gel electrophoresis 
Resolution of high molecular weight components was completed with a separating gel of 
7.5% polyacrylamide utilizing the method of Laemmli (1970). Low molecular weight 
components were separated with a 12% polyacrylamide gel. A 4% stacking gel was used for 
all samples (appendix C). Native gels were prepared without SDS in a manor identical to that 
described above. Samples for reversed polarity native gels were prepared with a triple strength 
(3x) sample buffer containing 40% glycerol (v/v), 4% Tris-HCl (w/v) and methyl-green set to a 
pH of 8.9. Such gels were run in buffer excluding SDS. All bench-top gel staining and western 
blotting techniques took place at room temperature on a rotational shaker set at 60 rpm. 
A Coomassie R250 staining solution was prepared with 0.025% Coomassie Brilliant 
Blue R250 (w/v), 40% methanol (v/v), 7% acetic acid (v/v) in water. Initial staining was 
performed for 1 hour. Destaining was done with several changes of a 40% methanol (v/v), 7% 
acetic acid (v/v) mixture until a sufficiently clear background was attained. Destained gels were 
photographed and stored in 5% glycerol (v/v). 
Periodic acid oxidizes carbohydrates, such as those in the O-polysaccharide and core 
region of LPS, and activates them for reaction with silver. The procedure of Bio-Rad silver 
staining was used (appendix A) with periodic acid used in place of dichromate as the oxidizer. 
The polyacrylamide gel was fixed in 50 mL fixed containing 40% methanol (v/v), 10% acetic 
acid (v/v) in triple distilled water for 30 minutes and then discarded. Periodic-acid based 
oxidizer [50 mL, 0.7% periodic acid (w/v), 40% ethanol (v/v), 5% acetic acid (v/v)] was 
added, incubated for 5 minutes and discarded. The contents were rinsed with five changes of 
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distilled water over ten minutes. Silver reagent was added (50 mL Bio-Rad silver staining 
solution diluted 1:10 in triple distilled water), incubated for 20 minutes and discarded. The gel 
was lightly rinsed for 30s with distilled water. Developer (1.6% w/v Bio-Rad developer 
powder in water) was added and allowed to incubate until bands were visually detected. A 50 
mL solution of stop bath (5% (v/v) acetic acid) was added to quench the silver reaction. The 
gel was subsequently stored in 5% (v/v) glycerol. 
Molecular weight standards were obtained and electrophoresed with each gel 
(Appendix D). A prestained broad range set of molecular weight standards was used for 
samples run on SDS-PAGE (Bio-Rad Laboratories, Mississauga, Ontario). Prestained 
Rainbow markers were utilized (AmershamPharmacia Biotech) for Western blotting 
experiments. 
Proteins were electro-blotted onto a nitrocellulose membrane (Hybond, ECL 
Chemicals, Amersham Pharmacia Life Sciences) in a BioRad mini Protean-2-electrotransfer 
apparatus. Transfer buffer comprised 3 g/L (w/v) Trisma-base (Sigma Chemicals, St. Louis, 
Minn., USA), 14.4 g/L (w/v) glycine and 20% (v/v) methanol with water. Binding sites were 
blocked with 5% (w/v) blocking solution reagent (ECL blocking agent. ECL Chemicals 
Amersham Pharmacia Life Sciences) in PBS with 0.1% (v/v) Tween-20 (PBS-Tween) 
incubated for 1 hour at room temperature (22°C). The membrane was washed for 10 minutes 
in PBS-Tween, followed by 3 subsequent washes of 5 minutes each. Serum (primary detector 
antibody) was diluted either in 1:50 or 1:1000 v/v in PBS-Tween and incubated for 1 hour in 
PBS-Tween as before. The membrane was washed for 10 minutes in PBS-Tween, followed by 
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3 subsequent washes of 5 minutes each. The indicator antibody (Caltag, CA., USA) goat anti-
mouse (or anti-rabbit) Heavy + Light chain IgG antibody conjugated to horseradish peroxidise 
(HRP)) was diluted 1:30,000 or 1:3000 (v/v) in 50 mL of PBS-Tween and incubated for 1 
hour. The membrane was then washed in PBS-Tween as noted above and then transferred 
onto a clean, dust-free sheet of acetate. ECL detection fluid (ECL Chemicals, Amersham 
Pharmacia Life Sciences) was aliquotted onto the membrane, incubated for 1 minute and then 
removed. A second strip of acetate was layered on top of the membrane and transferred, 
under safelight conditions, into an exposure cassette containing sensitized X-ray film (ECL 
Hyperfilm, Amersham Pharmacia Life Sciences). Film was developed in a Kodak GBX 
developer by inspection, fixed and stored. 
2.4 Protein determination 
A BCA assay was utilized for protein determination (Smith et al, 1985). Assays were 
performed in a 96-well, flat bottom, sterile microtitre plate (Nalgene). Samples were diluted 1:1 
with BioRad BCA working solution of 50 parts BCA Reagent A (1% (w/v) bicinchoninic acid, 
2% (w/v) NaHC0 3 .H 2 0 , 0.16% (w/v) Na tartrate, 0.4% (w/v) NaOH, 0.95% (w/v) 
NaHC0 3 , pH 11.25) to 1 part Reagent B (4% (w/v) CuS0 4 ) . Samples were incubated at 
room temperature for 10 minutes and read at 595nm in a Thermomax microtitre plate reader 
(Molecular Devices, Sunnyvale, CA). Protein concentrations were interpolated from a curve 
constructed from bovine serum albumin standards and the results were analyzed with the 
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Softmax software (Molecular Devices, Sunnyvale, CA) using the supplied 4-parameter fit. The 
linear region of this 4-parameter fit normally provided three useful data points for determining 
the protein content of the sample. 
2.5 Enzyme analysis of F. tularensis LVS supernatants 
A set amount of enzyme (0.83 ug) was incubated with a set amount (1.88 ug) of F. 
tularensis LVS liquid culture supernatant, as interpolated from BSA standards, at 37 °C for 12 
hours. Enzymes were obtained from various sources (Proteinase-K (3.4.21.14 Sigma, P6556, 
12 U/mg), lipase (Mann Research. Crude Porcine Pancreas, 3.2 U/mg), DNAase (3.1.21.1, 
Sigma, DN25, 600 U/mg), RNAase (Sigma, Bovine Pancreas IA, 0.36 U/mg) and lysozyme 
(3.2.1.17, Sigma, L6876, 62000 U/mg)). Enzyme was inactivated with addition of SDS loading 
buffer and subsequently boiled prior to loading onto an SDS gel. 
2.6 Partial purification of F. tularensis LVS cell lysates 
A Pharmacia Mono-Q 10/10 column was equilibrated with 10 mM HEPES buffer, pH 
7.4, containing 1 mM DTT and 1 mM EDTA. Cell lysate was applied to the column using a 50 
mL loop and washed with equilibration buffer until baseline absorbance was achieved. Material 
bound to the quaternary amine column was eluted by a KC1 gradient (0.3 M to 1.5 M) over 80 
minutes with a flow rate of 1.0 mL/min. Proteins eluting from the column were monitored in-line 
at 214nm with 0.5 absorbance units full scale (10% offset) and a chart speed of 2 mm/min. 
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Fractions were collected in 1 minute intervals and stored at 4°C until required. 
2.7 Tissue culture and cytokine determination 
Modified minimum essential medium (mMEM) (Hertz et al., 1982) was prepared for 
cell culture. The macrophage cell line J774.1 was grown on T75 tissue culture plates in mMEM 
without phenol red, supplemented with streptomycin (10 ug/mL), penicillin (10 U/mL), 
fungizone (0.25 jag/mL) and 5% (v/v) horse serum (Flow Laboratories, Mississauga, Ontario, 
Canada). Cells were passaged every 6 days to prevent growth beyond the monolayer and to 
maintain the cell line. Prior to treatment. J774.1 cells were plated on 96 well plates at a 
concentration of 5000 cells/well. 
J774.1 murine macrophages were seeded into sterile 96 well plates (Falcon) at a 
concentration of 5000 cells/well. At a concentration of 10 5 cells/well (approximately 6 days 
growth), cells were treated for 24 hours with various solutions. The NO produced during the 
24 hour period was determined by nitrate analysis (Green, et al. 1982). The media was 
removed to a fresh 96 well plate and added to an equal volume (1:1) of Griess reagent (1% 
sulphanilamide, 0.1% napthylethylenediamine dihydrochloride, 2.5% v/v H 3 P 0 4 , Sigma 
Chemicals). After incubation at room temperature for 10 minutes, the plate was read at 540 
nm in a Thermomax microtitre plate reader (Molecular Devices, Sunnyvale, CA, USA). 
Sodium nitrate was used as a standard for nitrate quantitation. 
Cell viability was assessed using Alamar Blue (AccuMed International, Inc., Westlake, 
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OH, USA). The dye was added 24 hours post treatment to a final concentration of 10% (v/v) 
and allowed to incubate at 37 °C for 5h. The absorbencies (570-600 nm) were read on a 
Thermomax titer plate reader (Molecular Devices, Sunnyvale, CA, USA). 
2.8 Animal care and handling 
Mice (balb/c or CD1, female, 19-21 g, 35 days old) were acquired from Charles River 
(St. Constant, Quebec, Canada). Mice were cared for in accordance with the guidelines set by 
the Canadian Council for Animal Care. All procedures were reviewed and approved by the 
DRES Animal Care Committee (members consist of a veterinarian, scientists and lay people 
from the community). Protocol JC-98-02 was used for this study. 
2.9 Preparation of anti-Tularemia serum 
To raise anti-Tularemia mouse sera, twenty balb/c mice were first vaccinated with the 
B. abortus O-polysaccharide (OPS). Each mouse was given 1 ug OPS in 0.1 mL sterile saline 
by the intraperitoneal route (IP). Two weeks following vaccination, the mice were infected via 
the interperitoneal route with 10 LD 5 0 of F. tularensis LVS diluted in 0.1 mL sterile PBS. 
Infected mice were then placed into isolator cages (with HEPA filter tops) within an operating 
BioSafety Cabinet. The cages were then placed into a HEPA filtered Animal Isolator (Thoren 
Caging, Toronto, Canada). The mice were monitored for 2 weeks. Twelve mice survived 
(60% of the OPS vaccinated mice survived 10 LD 5 0 of F. tularensis LVS) and these were 
sacrificed for anti-Tularemia serum. 
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Infection by the intranasal route was completed after mice were anaesthetized with 1:10 
diluted Somnitol™. A volume of 0.010 mL of the bacterial suspension was delivered to a 
single nostril. Blood was collected into 1.5 mL Eppendorf centrifuge tubes. Small volumes 
(0.1-0.3 mL) were collected utlizing a 26 gauge needle from the warmed tail veins. Larger 
volumes (1 mL) were collected by performing a heart-puncture with a 1 mL syringe with a 26 
gauge needle attached. The blood was centrifuged (5,000 x g, room temperature, 10 minutes) 
and the serum removed. Glycerol was added to the serum for a final concentration of 10% 
(v/v). These were stored frozen at -70°C until required. 
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3.0 Results 
3.1 Development of mouse ant i -F. Tularensis antibodies 
Commercially available rabbit anti-F. tularensis antiserum (Difco, Detroit, Mich. USA) 
was initially used in this study but was abandoned. This antibody was used as a probe on a 
Western blot, following SDS-PAGE of F. tularensis LVS cell lysates. The antibody did not 
appear to identify any significant components in the bacterial lysates possibly because these 
animals that produced these antibodies were immunized with killed, rather than living (i.e., toxin 
secreting) bacteria. 
Sera were obtained from mice which were infected with B. abortus. Two weeks post 
infection, sera was collected, filter sterilized, and then sterility checked. This antibody were 
used on Western Blots of SDS-PAGE separated lysates and sterile supernatants of F. 
tularensis. There were no specific bands detected on Western Blot, deemed to be a negative 
result. 
Many of the components of F. tularensis and Brucella abortus cross-react (Behan, 
1982). Using this information, we sought to protect mice with an OPS based Brucella vaccine 
and then challenge them with F. tularensis LVS. We hypothesized that these 'Brucella-
primed' mice may possess immunity towards challenge against a second intracellular pathogen 
and that this immunity would be towards specific components important in the pathogenesis of 
Tularemia. 
Mice were then immunized with the Department of National Defense (DND) 
experimental Brucella abortus 1119-3 O-polysaccharide (OPS) vaccine, not to raise 
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antibodies against Brucella, but to provide them with cross-protection against Tularemia. Mice 
infected with 10 LD 5 0 of F. tularensis typically die before they can raise antibodies to its 
virulence factors. However, once partially protected with a.nt\-Brucella vaccine, it was 
observed that most animals survive even this high dose of infection. It was hoped that the 
surviving mice would have raised antibodies to immunologically significant components 
expressed, or exposed by the live bacterium but not found in killed cells. 
Little difference was observed between unvaccinated mice and Brucella OPS 
vaccinated mice given 10 LD 5 0 of F. tularensis over the first 3 days. All of the hosts became 
lethargic and less responsive to handling. After three days, health of the unvaccinated mice 
deteriorated until all but one of the 20 controls perished (the lone survivor was marginally alive 
for a month and then recovered in the second month). In contrast, most of the vaccinated mice 
quickly recovered and of 20 mice, 12 or 60% fully recovered (40% perished). Sera from the 
12 vaccinated survivors was obtained, pooled and stored at -70°C. However, sera stored at 
-70°C appeared to loose specificity both with time and increasing number of freeze/thaw 
cycles. 
3.2 Identification of a 52 kDa component in F. tularensis supernatant 
Supernatant fractions from liquid broth cultures of F. tularensis LVS were lyophilized 
and then, separated by SDS-PAGE. These gels were transblotted onto nitrocellulose and 
probed with the B. suis primed, F. tularensis LVS challenged murine serum with a 1:50 
dilution (Figure 1 and Figure 2). Figure 1 denotes a prominent band corresponding to a 
molecular weight of 52 kDa in lanes 1 through six corresponding to the six subcultures 
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completed. This band is quite prominent in Lanes 1 and 5. Protein loaded onto these two gels 
was not standardized and differing levels of identification are likely due to differing amounts of 
antigenic material expressed within the various subcultured samples. In broth subculture 3 (Lane 
3 of Figure 1), a doublet band was observed possessing molecular weights of 52 and 51 kDa, 
relative to protein standards. There were no other immunologically active bands detected. The 
same 52 kDa band is visible in the separated components visible on the Western blot in Figure 
2. The component appeared in all of the CSM broth subcultures electrophoresed on the SDS-
PAGE (subcultures 1, 2, 4 and 5 corresponding to lanes 1, 2, 3 and 4). Here, the doublet band 
was not visible. 
Non-lyophilized, filter sterilized F. tularensiss LVS supernatants, concentrated by 
pressure ultrafiltration with a MWCO membrane of 30 kDa, were separated by SDS-PAGE, 
transferred onto nitrocellulose and probed with a 1:1000 dilution of the Brucella-primed anti F. 
tularensis antiserum (Figure 3). A band was present at 52 kDa in all of the lanes corresponding 
with ultrafiltrated concentrates (lanes 2, 4, 6, 8, 10, 11 and 12 in Figure 3). This 52 kDa 
component was not detected in the lanes corresponding to ultrafiltrated filtrates (lanes 3, 5, 7 
and 9 in Figure 3) indicating the 52 kDa component was successfully concentrated. There are 
several other bands visible corresponding with approximate molecular weights of 90, 48 and 34 
kDa. It was thought that these minor bands were likely due to non-specific binding from the 
higher dilution of primary antibody used. Lane 4, in Figure 3, corresponding to the ultrafiltration 
concentrated supernatant is darkly stained, likely from increased lysis that occurred in this 
sample. 
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Figure 1 
Immunoblot (Western) of F. tularensis cellular components from lyophilized samples. Molecular 
weight determination of antigenic components present in F. tularensis LVS supernatant (July 23, 
1998). Samples electrophoresed on 8% SDS PAGE and transblotted as described. Primary 
antibody: 1:50 Brucella-pnmed anti F. tularensis murine antisera. Secondary antibody: 1:3000 
Caltag anti-mouse-HRP. Lane 1: broth subculture 1, lane 2: broth subculture 2, lane 3: broth 
subculture 3, lane 4: broth subculture 4, lane 5: broth subculture 5, lane 6: broth subculture 6, lane 
7: 5uL Rainbow MW marker (weights indicated), lane 8: membrane with Rainbow MW markers 
indicated. 
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Figure 2 
Immunoblot (Western) of F. tularensis cellular components from lyophilized samples. 
Samples electrophoresed on 12% SDS PAGE and transblotted as described. Primary 
antibody: 1:50 Brucella-primed anti F. tularensis murine antisera. Secondary 
antibody: 1:3000 Caltag anti-mouse-HRP. Lane 1: broth subculture 1, lane 2: broth 
subculture 2, lane 3: broth subculture 4, lane 4: broth subculture 5, lane 5: 5|iL 
Rainbow MW marker. 
34 
MWxlO" 3 M W x l O - 3 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 
Figure 3 
Immunoblot (Western) of F. tularensis LVS liquid culture supernatant filtrates 
and concentrates from pressure ultrafiltration preparation Samples 
electrophoresed on a 10% SDS PAGE. Primary antibody: 1:1000 Brucella-
primed anti F. tularensis murine antisera. Secondary antibody: 1:3000 Caltag 
anti-mouse-HRP. Lane 1: BioRad H/L MW marker (5pL), lane 2:1° Amicon 
concentrate, lane 3: 1° Amicon filtrate, lane 4: 2° Amicon concentrate, lane 5: 
2° Amicon filtrate, lane 6: 3° Amicon concentrate, lane 7: 3° Amicon filtrate, 
lane 8: 4° Amicon concentrate, lane 9: 4° Amicon filtrate, lane 10: 5° 
concentrate, lane 11:6° concentrate, lane 12:7° concentrate,, lane 13: Rainbow 
MW marker (5uL), lane 14: Rainbow MW marker (5 jiL) nitrocellulose membrane: 
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3.3 Native PAGE of F. tularensis supernatant 
F. tularensiss LVS cultures were grown for one to eight days, supernatant fractions 
concentrated by pressure ultrafiltration and centriprep filtration, and then separated by PAGE 
under non-reducing (no SDS) conditions prior to being transblotted onto nitrocellulose and 
probed with anti F. tularensis antiserum (Figure 4). Samples in lanes 2 through 5 were 
prepared using pressure ultrafiltration only, and samples in lanes 6 through 9 were prepared 
using ultrafiltration and centriprep filtration. The gel was loaded with 292 ng protein per well, 
as determined by a BCA assay. A band with an apparent molecular weight of 52 kDa was 
identified on the immunoblot (Figure 4) in all sample lanes (Lanes 2 through 9). This 52 kDa 
band was present in increasing intensity up to a maximum after 5 days of growth (lane 6) and 
then remained in equivocal intensity. In lanes 6 and 7 (5 and 6 days growth), the 52 kDa band 
appeared as a doublet. There were other bands present on the gel, with apparent molecular 
weights of approximately 66 kDa and 100 kDa which appeared above the 52 kDa band in all 
sample lanes. There was also a band which appeared after 96 hours of growth; i.e., the band 
appeared only in lanes 6 through 9, but was absent from lanes 2 through 5. This second band, 
appearing with an approximate molecular weight of 38 kDa corresponded with the samples that 
were secondarily processed with the added step of the centriprep filtration. 
The same samples were electrophoresed by PAGE, with reversed polarity, under non-
reducing conditions (no SDS), transblotted onto nitrocellulose and probed as above. No 
antigenic material was identified (Figure not shown). 
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Figure 4 
Immunoblot (Western) Characterization of F. tularensis LVS cellular 
components. Samples preparred and electrophoresed under normal polarity 
on a 7.5% native (no SDS) gel. Protein concentration of samples standardized 
at 292 ng/well. Primary antibody: 1:50 5race//a-primed anti F. tularensis 
murine antisera. Secondary antibody: 1:3000 Caltag anti-mouse-HRP Lane 
1: BioRad H/L MW marker (5uL), Lane 2: 24 hours growth, Lane 3: 48 hours 
growth, Lane 4: 72 hours growth, Lane 5: 96 hours growth, Lane 6: 5day 
growth, Lane 7: 6day growth, Lane 8: 7day growth, Lane 9: 8day growth. 
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3.4 Identification of antigenic components in F. tularensis cell lysate 
Sonicated F. tularensis LVS cell lysates were prepared as described. A dilution set of 
cell lysates was prepared and electrophoresed by SDS-PAGE, transblotted onto nitrocellulose 
and probed (Figure 5). Shown in Figure 5 is a sample result of 1.55 ng probed cell-lysate 
material (Lane 2) beside a set of pre-stained molecular weight markers (Lane 1). Two major 
antigenic bands were identified: one with an apparent molecular weight (MW) of 17 kDa and 
the other with a MW of 52 kDa (Figure 5). Both bands were present in all dilutions and 
decreased with intensity with decreasing F. tularensis LVS cell lysate concentration. There 
were other immunogenic bands visible, but in lesser intensity, corresponding with molecular 
weights of approximately 34 kDa, 85 kDa and 100 kDa. The 52 kDa and 17 kDa antigenic 
bands did not correspond with any component visible in the Coomassie stained gel (Figure not 
shown). 
F. tularensiss LVS cell lysate was separated by PAGE under non-reducing (native, 
containing no SDS) conditions, transblotted onto nitrocellulose and probed (Figure 6). A 
dilution set of cell lysates was created. Two lanes are shown to indicate the antigenic material 
detected. Sample loading corresponds with 12.4 ng and 6.2 ng for Lanes 2 and 3, 
respectively. Two major bands were detected on the immunoblot (see arrows) in the sample 
lanes (Lane 2 and 3). This indicates that the antigenic component of interest is negatively 
charged. No molecular weight determination was performed on these samples, as the markers 
were not visible. There was antigenic material present in the wells which did not migrate into 
the gel matrix (shown at the top of the gel). 
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Figure 5 
Immunoblot (Western) characterizataion of F. tularensis LVS liquid culture cell 
lysate. Samples prepared and electrophoresed on 7.5% SDS-PAGE. Gel 
transblotted onto nitrocellulose membrane and probed under the following 
conditions: Primary antibody: 1:1000 Brucella-primed anti F. tularensis murine 
antisera. Secondary antibody: l:3000Caltaganti-mouse-HRP..Lanel:BioRadH/L 
MW marker (5pL), Lane 2: F. tularensis LVS liquid cell culture lysate 1.55ng. 
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Figure 6 
Immunoblot (Western) characterizataion of F. tularensis LVS liquid culture cell 
lysates using Native PAGE. Samples prepared and electrophoresed under 
normal polarity on a 7.5% Native (no SDS) PAGE. Gel transblotted onto 
nitrocellulose membrane and probed under the following conditions: Primary 
antibody: l:1000Brwce//a-primedantiF. tularensis murine antisera. Secondary 
antibody: 1:3000 Caltag anti-mouse-HRP.. Lane 1: BioRad H/L MW marker (5uL), 
Lane 2: F. tularensis LVS liquid cell culture lysate (12.4ng), Lane 3: F. 
tularensis LVS liquid cell culture lysate (6.2ng). 
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3.5 LPS stain (silver) of Mono-Q fractionated F. tularensis supernatant 
F. tularensiss LVS cell lysate was fractionated on a Mono-Q anion exchange column 
(Figure 11). The collected fractions (fractions 11 and 22 through 33) were separated by SDS-
PAGE and stained for lipopolysaccharide, using a periodic acid oxidizer and a silver-based 
staining agent (Figure 7). Numerous components were identified which contained 
polysaccharide moieties. Fractions 24 and 25, corresponding to Lanes 5 and 6, contained a 17 
kDa component (see arrowhead). If this represents the TUL4 17 kDa component of F. 
tularensiss, then it would confirm its extracellular nature. A band with an approximate 
molecular weight of 23 kDa appeared strongly (see arrow) in fraction #23 (Lane 4) and 
decreased progressively to fraction #30 (Lane 11). A band of 30 kDa was present in fractions 
#22 through #25 situated just above the 23 kDa component. No component with a molecular 
weight of 52 kDa was identified within any of the Mono-Q 10/10 fractions, suggesting the 
intracellular nature of this component. 
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Figure 7 
Lipopolysaccharide (LPS) characterization of Mono-Q fractionated F. tularaensis 
LVS liquid culture components. Cellular components from January 31 (2°) F. 
tularensis LVS liquid culture was prepared for column chromatography as described. 
Fractions collected and electrophoresed on a 7.5% SDS PAGE. Gel was stained for 
LPS components using the technique by Hitchcock and Brown (1983). Lane 1: 
BioRad H/L MW marker (10|iL), Lane 2: Fraction #11, Lane 3: Fraction #22, Lane 4: 
Fraction #23, Lane 5: Fraction #24, Lane 6: Fraction #25, Lane 7: Fraction #26, Lane 
8: Fraction #27, Lane 9: Fraction #28, Lane 10: Fraction #29, Lane 11: Fraction #30, 
Lane 12: Fraction #31, Lane 13: Fraction #32, Lane 14: Fraction #33. 
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3.6 Enzyme treatment of F. tularensis supernatant 
Samples of a F.tularensis LVS concentrated supernatant were incubated with various 
enzymes to identify the characteristics of the 52 kDa antigenic component. Following incubation 
of 1.88 ,ug F. tularensis LVS supernatant with 0.83 tug enzyme for 24 hours and reaction 
quenching by SDS loading buffer, samples were separated by SDS-PAGE. The gel was 
transblotted onto nitrocellulose and probed with the 1:1000 Brucella-primed anti F. tularensis 
LVS sera (Figure 8). Samples are displayed in pairs of supernatant/enzyme and enzyme only. 
Lane 3 consists of the supernatant incubated with Proteinase-K. Lane 5 consists of the 
supernatant incubated with lipase. Lane 7 consists of the supernatant incubated with DNAse. 
Lane 9 consists of the supernatant incubated with RNAse. Lane 11 consists of the supernatant 
incubated with lysozyme. Molecular weight markers were placed in Lanes 1 and 13. Lanes 4, 
6, 8, 10 and 12 consisted of samples containing 0.83 ,ug Proteinase-K, Lipase, DNAse, 
RNAse and lysozyme, respectively. 
Six major antigenic components were identified in the stock F. tularensis supernatant 
(Lane 2) with molecular weights of 15 kDa, 17 kDa, 31 kDa, 34 kDa, 44 kDa and 52 kDa 
respectively (see arrows). Treatment of the F. tularensis supernatant with Proteinase-K 
obliterated the antigenic bands on the immunoblot (Figure 8, Lane 3). The Proteinase-K 
treated sample had no visible bands on the Coomassie R250 stained gel, whereas prior to 
digestion, there were bands visible (Figure not shown). There remained a large amount of low 
molecular weight material that ran with the gel front that was visible on the Coomassie R250 
stained gel (Figure not shown). 
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Lipase treated supernatant (Lane 5) lacked antibody identification of the 44 kDa and 
31 kDa components, when compared to the control untreated F. tularensis supernatant (Lane 
2). Lanes corresponding to RNAse and lysozyme treated supernatant (Lane 9 and 11, 
respectively) did not differ significantly from their corresponding control lane containing 
untreated F. tularensis supernatant (Lane 2). The same six antigenic components were 
detected in these lanes. There was no difference between the supernatant treated lanes on 
either the Coomassie Brilliant Blue R250 stained gel when compared to the control lane of 
untreated supernatant (Figure not shown). 
The lane containing DNAase treated supernatant (Lane 7, Figure 8) exhibited a 
decreased intensity of the 52 kDa component. There were numerous other changes in the six 
antigenic components when compared to the control lane (Lane 2). Besides the decreased 
intensity of the 52 kDa components, there was a second band, corresponding to approximately 
50 kDa. identified below the 52 kDa band. While the 44 kDa band was visible, a band with a 
molecular weight of 47 kDa was present. Interestingly, the 31 kDa band did not appear, rather 
a new band with a molecular weight of approximately 37 kDa was visible. There was also 
identified a component with a molecular weight of approximately 13 kDa. DNAse appeared to 
modify the 52 kDa component - possibly cleaving it into two secondary pieces of 37 kDa and 
13 kDa respectively. 
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Figure 8 
Enzyme characterization and immunoblot (Western) of antigenic F. tularensis 
liquid culture cellular components. Supernatant from Day7 of the multiday growth 
series used (7D). Supernatant (1.88ug) was treated with various enzymes (0.83|ig). 
Samples prepared and electrophoresed on a 7.5% SDS-PAGE and transblotted 
onto nitrocellulose. Membrane probed under the following conditions: Primary 
antibody: 1:1000 Brucella-primed anti F. tularensis murine antisera. Secondary 
antibody: 1:3000 Caltag anti-mouse-HRP Lane 1: BioRad H/L MW marker (5uL), 
Lane 2: 7D supernatant, Lane 3: Proteinase-K digested supernatant, Lane 4: 
Proteinase-K, Lane 5: Lipase digested supernatant, Lane 6: Lipase, Lane 7: DNAse 
digested supernatant, Lane 8: DNAse, Lane 9: RNAse digested supernatant, Lane 
10: RNAse, Lane 11: Lysozyme digested supernatant, Lane 12: Lysozyme, Lane 13: 
BioRad Kailadoscope MW marker (6uL). 
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3.7 Probing panel of 5 bacteria with F.tularensis LVS mouse serum 
The antigenic activity present in 4 bacterial cell lysates was compared to the activity 
present in the cell lysate of F. tularensiss. These additional bacteria. Staphylococcus aureus 
ATCC 25923, Escherichia coli 0157:H7, Salmonella godesburg and Pseudomonas 
maltophilia 555, were chosen because they all possess sugar components similar to that of the 
Brucella OPS which was utilized to immunize the mice that were subsequently challenged with 
F. tularensis LVS to create sera used in these, and previous experiments. The bacterial 
product was prepared by sonificaton as described. Sterile, cell-free bacterial product, at a 
standard concentration of 12.4 /ug, from the five bacteria lysates was separated by SDS-
PAGE. The gel was transblotted onto nitrocellulose and probed with the Brucella primed anti 
F. tularensis antibody in a dilution of 1:1000 (Figure 9A). Molecular weight markers were run 
in Lanes 1 and 7. There was a great deal of background bands appearing on the Western blot. 
Brucella primed anti F. tularensis antibody identified two major components in each of the six 
sample lanes. In Lanes 2 and 7 (F. tularensis LVS), the major bands corresponded with MW 
of 52 kDa and 17 kDa, respectively (arrows). Components with these molecular weights were 
also identified in approximately the same intensity in Lanes 3, 4 and 6 (E. coli, S. godesberg 
and P. maltophilia, respectively). In Lane 5 (S. aureus), a component with a molecular weight 
of approximately 50 kDa was identified, likely Protein-A. A low molecular weight component 
of 17 kDa was also identified in Lane 5 (5. aureus). The detection of the 52 kDa and 17 kDa 
components showed these as roughly equal in intensity to each other, but less intense than the 
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protein-A component. The amount of background banding present was likely indicative of 
overdevelopment. 
A similar gel was prepared, using the cell-free sonicated products of F. tularensiss 
LVS, Staphylococcus aureus ATCC 25923, Escherichia coli 0157:H7, Salmonella 
godesburg and Pseudomonas maltophilia 555. These products were loaded at a constant 
protein concentration of 12.4 /ug per well and separated by SDS-PAGE as described. After 
transblotting onto nitrocellulose, the membrane was probed with a naive (unexposed to either 
F. tularensiss and unvaccinated) balb/c mouse sera as a primary antibody (Figure 9B). No 
molecular weight markers are shown on this Western blot. The naive mouse sera identified 
several components within all five of the cell lysates (Figure 9B). In Lane 3 (S. aureus), a 50 
kDa component was strongly identified. This component likely corresponds to Protein-A (see 
arrow). Also, in lanes 1, 2, 3 and 5 (E. coli, S. godesberg, S. aureus and F. tularensis), the 
17 kDa component was again identified. The detection of this 17 kDa component was similar in 
intensity to that of the protein-A (50 kDa) component. The 52 kDa band was not detected in 
E. coli 0157:H7, S. godesberg or P. maltophilia using naive serum (Lanes 1, 2 and 4). There 
was a very low level of detection of a 52 kDa component in Lane 5 (F. tularensis). 
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Figure 9 
Immunoblot (Western) comparison of antigenic components in F. 
tularensisXo LVS to a panel of four other clinically important bacteria. SDS-
PAGE of processed bacterial cell lysates. Samples prepared and 
electrophoresed on a 7.5% SDS-PAGE of 1.0mm thickness as described and 
transblotted onto a nitrocellulose membrane. Protein concentrations of 
lysates standardized at 12.4 p.g per well. 
Immunoblot A: Membrane probed under the following conditions: primary 
antibody: 1/1000 DND Brucella/F. tularensis mouse antisera, secondary 
antibody: 1/3000 Caltag anti-mouse-HRP. Lane 1: BioRad H/L MW marker 
(5|iL), Lane 2: F. tularensis cell lysate, Lane 3: E. coli cell lysate. Lane 4: S. 
godesberg cell lysate, Lane 5: S. aureus cell lysate, Lane 6: P. maltophilia 
cell lysate, Lane 7: F. tularensis cell lysate, Lane 8: Rainbow MW marker 
Immunoblot B: Membrane probed under the following conditions: Primary 
antibody: 1/1000 naive mouse serum (Nov 95 balb/c), secondary antibody: 
1/30000 Caltag anti-mouse-HRP Lane 1: E. coli cell lysate, Lane 2: S. 
godesburg cell lysate, Lane 3: S. aureus cell lysate, Lane 4: P. maltophilia 
cell lysate, Lane 5: F, tularensis cell lysate. 
(3uL) 
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3.8 Probing F.tularensis LVS lysate with anti-F. tularensis antibodies 
Sonicated, cell-free F. tularensis LVS cell lysate was prepared as described. A 
dilution set of cell lysates was prepared and electrophoresed by SDS-PAGE. transblotted onto 
nitrocellulose and probed with either the Brucella-primed anti-F. tularensis LVS serum (Figure 
10B) or Canadian Bioconcepts Rabbit anti F. tularensis antibody (Figure 1QA). Also 
electrophoresed was a set of pre-stained molecular weight markers (Lane 1 in Figure 10A and 
10B). Shown are respective samples of the result of 3.1 /ug F. tularensiss LVS cell lysate 
sample loaded onto the gel (Lane 2 in Figure 10A and 10B) and probed with the two 
antibodies. Other lanes appeared similar, with identical bands visible in greater or lesser 
intensity, depending on the greater or lesser amount of sample loaded onto the gel. 
Canadian Bioconcepts anti-F. tularensiss rabbit serum, prepared using killed whole-
cell F. tularensis LVS components, identified background components within the F. tularensis 
cell lysate (Figure 10A). While there were bands present, there was no specific band that was 
of interest. A Western blot of F. tularensiss LVS components was prepared and probed 
using Naive (not exposed to either Brucella or Francisella) mouse sera. A similar background 
banding pattern was present as was visible in Figure 10A. 
Two major antigenic bands were identified by the Brucella primed anti-F. tularensiss 
LVS sera (Figure 10B): one with a molecular weight of 17 kDa and the other with a MW of 52 
kDa (see arrows). Both bands were present in all dilutions and decreased with intensity with 
decreasing F. tularensis LVS cell lysate concentration. This antigenic band did not correspond 
with any component visible in the Coomassie stained gel (Figure not shown). Also present, but 
49 
weaker in intensity, were bands at 34 kDa and approximately 100 kDa. Overall, there was a 
specific identification of two components: 52 kDa and 17 kDa. We suggest that the different 
banding patterns present between the DND Brucella primed sera and the Canadian 
Bioconcepts sera may be due to the live infection process that occurred in the preparation of 
the DND sera. 
50 
1 2 1 2 
Figure 10 
Immunoblot (Western) comparison of DND Brucella-primed anti F. tularensis murine 
antisera with rabbit anti-F. tularensis antisera. SDS-PAGE of F. tularensis LVS liquid 
culture cell lysates. Samples prepared and electrophoresed on a 7.5% SDS-PAGE and 
transblotted onto a nitrocellulose membrane Membrane probed under the following 
conditions: 
A: Primary antibody: 1/1000 Canadian bioconcepts Rabbit anti-F. tularensis antisera, 
secondary antibody: 1/3000 Sigma anti-rabbit-HRP. Lane 1: BioRad H/L MW marker 
(5/iL), Lane 2: F. tularensis LVS liquid cell culture lysate 3.1 ng. 
B: Primary antibody: 1:1000 Brucella-phmed anti F. tularensis murine antisera, 
secondary antibody: 1:3000 Caltag anti-mouse-HRP. Lane 1: BioRad H/L MW marker 
(5uL). Lane 2: F. tularensis LVS liquid cell culture lysate 3.1 ng. 
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3.9 Mono-Q separation of F. tularensis LVS cell lysate components 
Sonicated, cell-free F. tularensis LVS cell lysate was prepared as described, loaded 
onto a Mono-Q anion exchange column and eluted with a KC1 gradient. Material eluted from 
the Mono-Q 10/10 column was monitored at 214nm and recorded (Figure 11). Fractions were 
separated by SDS-PAGE, transblotted onto nitrocellulose and probed with a 1:1000 dilution of 
the Brucella-primed anti-F. tularensis LVS sera as described previously (Figure 12). 
A molecular weight marker was electrophoresed in Lane 1. A 52 kDa band appeared 
in Lanes 5 through 11, corresponding to Fractions 25 to 30 (Figure 12), with the strongest 
band appearing in Fraction 28 (Lane 9). Lane 6 (Fraction 25) had multiple immunogenic 
components, including the 52 kDa component, the 17 kDa component as well as two with 
molecular weights of approximately 23 kDa and 20 kDa. Also noted was the presence of an 
immunogenic band visible in Fraction 24 and 25 (Lane 5 and Lane 6) with an approximate 
molecular weight of 17 kDa. These bands correspond to the 17 kDa material on visible on the 
LPS stained gel of the same column fractions (Figure 7). This further supports the extracellular, 
and immunogenic nature of the 17kDa component. Fraction 29, was chosen for use in tissue 
culture experiments, as it appeared to have the least amount of extraneous antigenic material 
with respect to the amount of 52 kDa material present. 
A second Mono-Q column was loaded with sonicated, cell-free F. tularensis LVS cell 
lysate. Material eluted from the Mono-Q 10/10 column was monitored at 214nm and 
recorded (Figure 13). Fractions were separated by SDS-PAGE, transblotted onto 
nitrocellulose and probed with a 1:1000 dilution of the Brucella-primed anti-F. tularensis LVS 
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sera as described previously (Figure 14). A molecular weight marker was electrophoresed in 
Lane 1. Fractions 23 through 34 were electrophoresed in Lanes 2 through 13. A 52 kDa 
band with high intensity appeared in Fractions 26 to 31 (Lanes 5 through 10) and at a lesser 
intensity in the other sample lanes. The 52 kDa component appeared as an immunogenic 
doublet in several of the lanes, for example Lanes 4 and 13 (Fraction 24 and 34). There were 
several other antigenic components present with molecular weights of approximately 80 kDa 
and 110 kDa, but these were of weaker intensity. Fraction 29 (Lane 8) possessed an 
acceptable purification of the 52 kDa component, with less non-52 kDa antigenic material than 
Fraction 28, and was chosen for use in vaccination experiments. 
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Figure 1 1 
Protein trace (214 nm) of Mono-Q separation of F. tulrensis LVS cell lysate 
components. Fraction number appears between tic marks at top. 
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Figure 12 
Immunoblot (Western) characterization of Mono-Q fractionated F. tularaensis LVS 
liquid culture components. Cellular components from January 31 (2°) F. tularensis 
LVS liquid culture was prepared for column chromatography as described. Fractions 
collected in one minute intervals and electrophoresed on a 7.5% SDS PAGE of 1.0mm 
thickness as described and transblotted onto a nitrocellulose membrane. Protein 
concentrations unknown. Membrane probed under the following conditions: primary 
antibody: 1/1000 DND Brucella/F. tularensis mouse antisera, secondary antibody: 
1/3000 Caltag anti-mouse-HRP. 
Lane 1: BioRad H/L MW marker (lOuL), Lane 2: Fraction #11, Lane 3: Fraction #22, 
Lane 4: Fraction #23, Lane 5: Fraction #24, Lane 6: Fraction #25, Lane 7: Fraction #26, 
Lane 8: Fraction #27, Lane 9: Fraction #28, Lane 10: Fraction #29, Lane 11: Fraction 
#30, Lane 12: Fraction #31, Lane 13: Fraction #32, Lane 14: Fraction #33. 
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Figure 13 
Protein trace (214 nm) of Mono-Q separation of F. tulrensis LVS cell 
lysate components. Fraction number appears between tic marks at top. 
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Figure 14 
Immunoblot (Western) characterization of Mono-Q fractionated F. tularaensis LVS liquid 
culture components. Cellular components from a F. tularensis LVS liquid culture was 
prepared for column chromatography as described. Fractions collected in one minute 
intervals and electrophoresed on a 7.5% SDS PAGE and transblotted onto a nitrocellulose 
membrane. Protein concentrations unknown. Membrane probed under the following 
conditions: primary antibody: 1/1000 DND Brucella primed anti-F. tularensis mouse 
antisera, secondary antibody: 1/30000 Caltag anti-mouse-HRP. 
Lane 1: BioRad H/L MW marker (10uL), Lane 2: Fraction #23, Lane 3: Fraction #24, Lane 
4: Fraction #25, Lane 5: Fraction #26, Lane 6: Fraction#27, Lane 7: Fraction#28, Lane 8: 
Fraction #29. Lane 9: Fraction #30, Lane 10: Fraction #31, Lane 11: Fraction #32, Lane 12: 
Fraction #33, Lane 13: Fraction #34. 
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3.10 Verification of pathogenicity of F. tularensis LVS 
Pathogenicity of the stored F. tularensis live vaccine strain was demonstrated in two 
strains of mice: balb/c and CD1 (sample sizes of n=6 and n=7, respectively). Mice were given 
a 250 LD 5 0 dose of F. tularensis LVS on day=0 via an intranasal route. Health of the mice 
was followed for a three week period. Approximately four days post infection, both sets of 
mice began to exhibit symptoms of infection. These symptoms included: shakiness, ruffled fur, 
closed eyes and general lethargic behavior when compared to uninfected mice. All mice 
succumbed to the disease process by the end of the three week period. 
All Balb/c mice (n=6) exposed to an IN dose of 250 LD 5 0 F. tularensis LVS 
succumbed by 11 days post infection (Figure 15). These mice exhibited symptoms sooner and 
than CD1 mice and expired, on average, 96 hours before the CDl mice. The disease process 
was fast, with only three days separating the first and last victim of the disease. All Balb/c mice 
exposed to 250 LD 5 0 F. tularensis LVS perished. 
All CDl mice (n=7) exposed to and IN dose of 250 LD 5 0 F. tularensis LVS 
succumbed by 15 days post infection (Figure 15). While CDl mice showed the same signs of 
infection as seen in the Balb/c set, the process did not seem as severe; i.e. the mice initially 
appeared less shaky and their fur was better maintained. CDl mice survived approximately 96 
hours longer than the Balb/c mice. Once established, the disease process was also fast with 
only four days separating the first and last victims. All mice (100%) within the CDl group died 
as a result of the F. tularensis infection. 
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days 
Figure 15 
Progression of Tularemia in control mice. 50 /iL IN injection of 250 LD 5 0 F. 
tularensis LVS in female balb/c and CDl mice (• - CDl n = 7, • - balb/c n = 
6) 
59 
3.11 Immunization and challenge of CDl mice 
Forty-nine CDl mice were used in a vaccination trial against F. tularensis LVS using 
subcellular components. At day=0, mice were given a 0.1 mL intraperitoneal (IP) injection of 
various components (Table 1). The components used to vaccinate mice were: 1) sterile PBS, 
2) lug B. abortus 1119-3 OPS, 3) lug B. melitensis 16M OPS/protein, 4) lug B. suis 145 
OPS/protein, 5) 2ug F. tularensis LVS cell lysate, 6) 2ug F. tularensis LVS cell lysate + lug 
B. suis 145 OPS/protein, 7) 2ug >30 kDa F. tularensis LVS supernatant (from pressure 
ultrafiltration), 8) 2ug >30 kDa F. tularensis LVS supernatant (from pressure ultrafiltration) + 
lug B. suis 145 OPS/protein, 9) Fraction 29 F. tularensis LVS cell lysate purification (Section 
3.2) and 10) Fraction 29 F. tularensis LVS cell lysate purification (Section 2.9) + lug B. suis 
145 OPS/protein. Five mice were in each of the test groups. Four mice were placed in the 
control group which received sterile PBS as a vaccination product. 
The level of protection incurred against F. tularensis LVS infection was gauged by 
superinfection with 250 L D 5 0 of F. tularensis LVS delivered intranasally (IN). Test mice in 
groups one through four were challenged with this dose 33 days post immunization. For groups 
five through eight, the F. tularensis LVS challenge was at 31 days and for groups nine and ten, 
the challenge was at 26 days. Mice were monitored for two weeks post infection for 
symptoms of infection. 
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The control group of four mice showed signs of disease five days post challenge with 
250 LD 5 0 of F. tularensis LVS. At nine days post challenge, all control mice succumbed to the 
disease (Table 2A). This corresponded with results from the initial potency trial which assessed 
250 LD 5 0 of F. tularensis LVS for infection (Table 1) and confirmed the pathogenicity of the 
F. tularensis LVS stock. 
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Injection type sample total percent 
size dead protection 
1 Control (0.1ml PBS) 4 4 , 0 
2 B.abortus 1119-3 OPS (lug) 5 3 40 
3 B.melitensis 16M OPS/protein (lug) 5 5 0 
4 145 OPS/protein (lug) 5 5 0 
5 F.tularensis cell lysate (2ug) 5 0 100 
6 B.suis OPS/1 day F.tularensis lysate 5 0 100 
7 >30 kDa supernatant (2ug) 5 4 20 
8 >30 kDa supernatant/B.suis OPS 5 0 100 
9 fraction #29 (52 kDa enriched) (2ug) 5 4 20 
10 fraction #29 (2ug)/B.suis OPS 5 3 40 
Table 1: 
Protection conferred upon CDl mice by various vaccine preparations. Mice were immunized with 
supernatants, lysates and fractions from F. tularensis LVS in combination with various Brucella 
OPS isolates. Two weeks post immunization, mice were challenged with a 50uL internasal injection 
of 250 LD 5 0 F.tularensis LVS and the disease process monitored. Data recorded three weeks post 
infection. 
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Table 2A 
F. tularensis Potency Trial. The pathogenicity of stock F. tularensis LVS was confirmed in both CDl and Balb/c mice strains. 
A time=0, mice were exposed by intranasal injection of 2.5 LD 5 0 F. tularensis and monitored for 18 days. Number of surviving 
(s) and dead (d) mice were recorded each day. 
Mice Number June 29 July 4 July 5 July 7 July 10 July 11 July 12 July 13 July 14 July 17 
Strain Exposed (Day 0) (Day 5) (Day 6) (Day 8) (Day 11) (Day 12) (Day 13) (Day 14) (Day 15) (Day 18) 
CDl 7 7s 7s 7s 7s 6s/ld 5s/2d 5s/2d 2s/5d ls/6d ls/6d 
Balb/c 6 6s 6s 6s 2s/4d ls/5d ls/5d ls/5d ls/5d ls/5d ls/5d 
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Table 2B 
Vaccine Protection Trial. The ability of various vaccine preparations to protect against F. tularensis LVS was tested in a CDl murine strain. At time = 0 mice were 
immunized with various bacterial cell extracts prepared from B. abortus, B. melitensis, B. suis, and F. tularensis. Between 26 and 33 days post infection, the mice 
were challenged with 250 LD 5 0 of F. tularensis and monitored for 12 days. Numbers of surviving (s) and dead (d) mice were recorded each day. 
Trial # Treatment Days Pre-Infection Days Post Infection 
No June02 June04 June09 July05 
(0) 
JulyO 
6(1) 
Julyl 
0(5) 
Julyl 
1(6) 
Julyl 
2(7) 
Julyl 
3(8) 
Julyl 
4(9) 
Julyl 
7(12) 
1 Control (0.1 mL PBS) 4 Immunised 250LD 5 0 4s 4s 2d/2s 3d/ls 4d 4d 
2 B. abortus 1119-3 OPS (lug) 5 Immunised 250LD 5 0 5s ld74s 2d/3s 2d/3s 3d/2s 3d/2s 
3 B. melitensis 16M OPS / 
protein (lug) 
5 Immunised 250LD 5 0 5s ld/4s 3d/2s 4d/ls 4d/ls 5d 
4 B. suis 145 OPS/protein (lug) 5 Immunised 250LD 5 0 5s 5s 3d/2s 4d/ls 4d/ls 5d 
5 F. tularensis cell lysate (2ug) 5 Immunised 250LD 5 0 5s 5s 5s 5s 5s 5s 
6 B. suis OPS ( l u g ) / F . 
tularensis cell lysate (2ug) 
5 Immunised 250LD 5 0 5s 5s 5s 5s 5s 5s 
7 <30 kDa supernatant (2ug) 5 Immunised 250LD 5 0 ld/4s 2d/3s 2d/3s 2d/3s 3d/2s 3d/2s 4d/ls 
8 <30 kDa supernatant / B.suis 
OPS 
5 Immunized 250 LD 5 0 5s 2d/3s 2d/3s 2d/3s 2d/3s 2d/3s 
9 fraction #29 (2ug) 5 Immunised 250 LD 5 0 ld/4s ld/4s ld/4s 3d/2s 4d/ls 4d/ls 
1 
0 
fraction #29 (2ug) / B.suis OPS 5 Immunised 250LD 5 0 5s 5s 5s ld/4s 2d/3s 3d/2s 
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3.12 Protection conferred w i t h F. tularensis LVS components 
Three different F. tularensis cell preparations were tested for their ability to impart 
immunity against infection; 1) F. tularensis LVS cell lysate prepared by sonication and fixed in 
azide, 2) >30 kDa F. tularensis LVS supernatant fraction obtained from pressure 
ultrafiltration and 3) Fraction 29 F. tularensis LVS cell lysate via Mono-Q anion exchange 
purification (Section 3.9). 
Mice receiving 2ug of the F. tularensis cell lysate exhibited no signs of infection (Trial 
5, Table 2). At the end of two weeks, no mice (0/5) perished as a result of the disease 
process. The cell lysate imparted 100% immunity to 250 LD 5 0 F. tularensis LVS infection. 
There appear to be components in the sonicated, azide-fixed F. tularensis LVS cell lysate 
which are able to prime the murine immune system sufficiently to protect the animal against 
superinfection. 
Mice receiving 2ug of the >30 kDa F. tularensis LVS supernatant (Trial 7, Table 2) 
preparation (from pressure ultrafiltration) exhibited a similar pattern to that of the control group 
which received a placebo of sterile PBS. By 12 days post infection, four out of five (4/5) of the 
mice succumbed to infection.. 
Mice which received 2ug of the Mono-Q separated F. tularensis LVS (Fraction 29) 
succumbed to infection (Trial 9, Table 2) in a manner similar to that of the control group, which 
was immunized with sterile PBS. At 12 days post infection, three out of five (3/5) of the mice 
succumbed to the disease. Fraction 29, which is a 52 kDa-enriched fraction, appeared to delay 
mortality, but did not impart immunity. 
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3.13 Protection conferred with Brucella spp. OPS components 
Three different Brucella spp. OPS preparations were tested for their ability to impart 
immunity against IN infection of 250 LD 5 0 F. tularensis LVS. One microgram of: B. abortus 
1119-3 OPS, B. melitensis 16M OPS/protein and B. suis 145 OPS/protein were used to 
immunize separate groups of mice (Table 1). 
Mice receiving the B. abortus 1119-3 OPS had a 60% death rate (3/5 mice) 12 days 
post infection (Trial 2, Table 2). All mice (5/5) receiving the B. melitensis 16M OPS/protein 
(Trial 3, Table 2) and the B. suis 145 OPS/protein (Trial 4, Table 2) died by 12 days post 
infection (100% mortality) (Table 2, Figure 16). 
3.14 F. tularensis IB. suis OPS cross protection 
CDl mice were injected with F. tularensis LVS cell lysate (2ug) combined with the B. 
suis 145 OPS/protein (lug) (Trial 6, Table 2). All mice survived (5/5). They showed no 
discernable signs of infection after 12 days. This 100% protection to 250 LD 5 0 F. tularensis 
LVS did not differ from the protection imparted by the F. tularensis cell lysate alone (Trial 5, 
Table 2 and Figure 16). 
Mice immunized with Fraction 29 (2ug) of the F. tularensis cell lysate fractionation 
combined with the B. suis 145 OPS/protein preparation (lug) exhibited 40% protection (Trial 
10, Table 2). An increase in the rate of protection, when compared to Fraction 29 without the 
B. suis OPS, was that of a single mouse and not statistically significant. Mice injected with this 
combination exhibited a similar pattern of sickness and death as was seen for mice receiving the 
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52 kDa-enriched fraction (Fraction 29) by itself (Table 2). 
CDl mice receiving the F. tularensis LVS supernatant (>30 kDa, from pressure 
ultrafiltration) combined with B. suis 145 OPS/protein (Trial 8, Talbe 2) exhibited a 100% 
survival rate, or 5/5 mice. This combination raised the level of protection of the >30 kDa 
supernatant against 250 LD 5 0 F. tularensis LVS from only 20% to 100% (Figure 16). 
Although the mice exhibited signs of sickness after five days, they rapidly recovered. At 12 
days, three of the five mice were mildly ill and appeared to be recovering. At the end of the 
study, all mice appeared to be functioning normally and healthy. The B. suis OPS, in 
combination with the material from F. tularensis LVS with a MW of >30 kDa, successfully 
protected the CDl mice from superinfection with 250 LD 5 0 F. tularensis LVS. 
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percent protection 
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Control (0.1ml PBS) 
B.abortus 1119-3 OPS (1 ug) 1 
B.melitensis 16M OPS/protein (1ug) 
B.suis 145 OPS/protein (1ug) 
F.tularensis cell lysate (2ug) 
1 1 1 1 
B.suis OPS/1 day F.tularensis lysate 
<30 kda supernatant (2ug) 
<30 kda supernatant/B.suis OPS 
fraction #29 (2ug) j 
fraction #29 (2ug)/B.suis OPS ~j 
4 i i + = = = = ^ 1 1 1—-i i 
0 20 40 60 80 100 
Figure 16 
Proportion of protection conferred upon CDl mice by various vaccine preparation, supernatants, 
lysates or fractions. 50pL internasal injection of 250 LD 5 0 F. tularensis LVS. Data recorded three 
weeks post infection. Sample size for all non-control groups is 5. 
3.15 Viability of J774.1 Cells in Response to F. tularensis supernatants 
The J774.1 murine macrophage cell line was utilized to investigate the cytotoxic effects 
of sterile F. tularensis LVS supernatants. The cell line was maintained, and prepared as 
described. The cells were treated with sterile F. tularensis LVS supernatant with the protein 
ranging from 0.002 mg/mL to 0.25 mg/mL (defined as 7D) and 0.002 mg/mL to 2.0 mg/mL 
(defined as 2°) respectively (Figure 17). A logarithmic scale was utilized to demonstrate the 
cell viability, due to the large range of protein concentrations used in the experiment. Viability 
was measured 24 hours post treatment, subjectively by direct observation and quantitatively 
using the non-toxic indicator dye, Alamar Blue (Accumed International Inc., Westlake, OH). 
Cell viability controls were created by using a sham inoculation of sterile PBS, which resulted in 
a determined cell viability of 1. Cell viability of zero was determined when cells were treated 
with an inoculation of sulfuric acid. 
Cells receiving the highest protein concentration of F. tularensis supernatant (from 
1.005 to 2.010 mg/mL) appeared rounded and detached from the tissue culture support. 
Untreated control cells maintained their bipolar morphology and remained attached to the tissue 
culture support. Cells treated with 1.005 to 2.010 mg/mL F. tularensis supernatant protein had 
a reduced cell viability relative to the untreated control cells (Figure 17). Cells receiving protein 
concentrations of 0.501 mg/mL and less, did not appear to exhibit deleterious effects as 
assessed by direct observation and viability dye analysis. Cytotoxic effects of the F. tularensis 
supernatant protein on J774.1 murine macrophages was limited to protein concentrations of 
1.005 mg/mL and higher. 
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Figure 17 
Alamar Blue cell viability of J774.1 macrophage cells in response to 24 hours treatment 
of two F.tularensis liquid culture supernatants. ( • - 7D culture supernatant, • - 2° 
culture supernatant). The range of cell viability was determined as: fully healthy (cell 
viability = 1), and complete cell death (cell viability = 0). 
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3.16 NO production in J774.1 Cells in Response to F. tularensis supernatants 
The J774.1 murine macrophage cell line was utilized to investigate the production of a 
rudimentary cytokine burst in response to sterile F. tularensis LVS supernatants. The cell line 
was maintained, and prepared as described. The cells were treated with sterile F. tularensis 
LVS supernatant with protein concentrations ranging from 0.002 mg/mL to 0.25 mg/mL 
(defined as 7D) and 0.002 mg/mL to 2.0 mg/mL (defined as 2°) respectively (Figure 18). A 
logarithmic scale was utilized to demonstrate the nitric oxide production, due to the large range 
of protein concentrations used in the experiment. The level of nitric oxide (NO) was measured 
24 hours post treatment with sterile F. tularensis LVS components and was compared against 
a standard curve created with stock sodium nitrite. 
The total amount of NO produced over the 24 hours followed a linear pattern between 
F. tularensis supernatant protein concentrations 0.031 and 0.503 mg/mL. At a protein 
concentration of 0.503 mg/mL, the total NO produced over the 24 hours period reached a 
maximal level of 11 ug/mL. This concentration was eleven times above the baseline level of NO 
production by the control cells over the same period. Nitric Oxide production decreased 
sharply in cells treated with two highest protein concentrations of 1.005 and 2.010 mg/mL F. 
tularensis supernatant protein, respectively, likely due to the cytotoxic effects of the treatment 
solution (see section 3.15). 
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Figure 18 
Nitric oxide (NO) production by J774.1 macrophage cells in response to treatment solution 
of two F. tularensis LVS supernatants for 24 hours (• - 7D liquid culture supernatant, • -
2° liquid culture supernatant). Nitrite levels compared against a standard curve created 
with stock sodium nitrite. 
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3.17 Viability of J774.1 murine macrophages - 52 kDa treatment 
The J774.1 murine macrophage cell line was used to investigate the cytotoxic effects of 
several F. tularensis LVS fractions. The cells were exposed for 24 hours to fractions from a 
Mono-Q separation of F. tularensis LVS liquid culture cell lysate (Section 3.9). Cells were 
treated with Fractions 19 through 33 from the Mono-Q fractionation of F. tularensis LVS cell 
lysate and were assessed 24 hours post exposure for: 1) viability and 2) amount of nitric oxide 
(NO) produced. 
The F.tularensis LVS cell lysate was eluted from the Mono-Q column by a KC1 salt 
gradient and collected in one minute intervals (Section 3.9). The J774.1 murine macrophages 
were treated for 24 hours with a salt gradient within the range which eluted the 52 kDa protein 
(0 to 1M KC1). These cells were assessed for viability and NO production. There was no 
decrease in cell viability indicated by either direct observation or analysis with vital indicator dye 
(Alamar Blue) noted within this range of salt concentration when compared to control wells 
receiving no KC1 gradient (data not shown). There was also no associated increase in NO 
production above background levels when compared to control wells receiving no KC1 
gradient (data not shown). 
The viability of J774.1 macrophages was measured 24 hours post treatment by direct 
observation and using the non-toxic indicator dye, Alamar Blue. Cell receiving aliquots of the 
Mono-Q fractionated F. tularensis LVS cell lysate did not differ morphologically from control 
cells receiving no treatment. Cells maintained their bipolar morphology and remained attached 
to the tissue culture support matrix. The viability of treated cells, by analysis with indicator dye, 
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did not differ from that of the control cells (data not shown). The Mono-Q fractionated F. 
tularensis LVS cell lysate had no cytotoxic effect on the J774.1 macrophages after 24 hours 
treatment. 
The production of nitric oxide in 24 hours by J774.1 murine macrophages in response 
to fractionated F. tularensis LVS cellular components was measured (Section 3.9, Figures 11 
and 12). Cells treated with Fractions 25 through 29 produced NO above the baseline level of 
production by the control cells over the same period (Figure 19). Cells receiving Fractions 25 
and 26 produced levels of NO 10 and 8 times above background levels, respectively (Figure 
19). This level NO induction corresponds with Lanes 6 and 7 in Figure 12. There are 
components within the Mono-Q fractionated F. tularensis LVS cell lysate which appear 
capable of inducing nitric oxide synthesis. 
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Figure 19 
Nitric Oxide (NO) production by J774.1 macrophage cells in response to treatment by Mono-Q separated 
fractions of F. tularensis LVS cell lysate for 24 hours. 
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4.0 Discussion 
The development of long term immunity to F. tularensis is a complex and largely 
unexplored area. The intracellular nature of this organism, coupled with its particularly high 
virulence, makes it difficult to study. Our research characterizes a cellular component which 
was identified through a novel method of vaccination. This component is highly immunogenic, is 
capable of inducing a cytokine response and imparting some degree of protection to infection. 
4.1 Antigenic components of F. tularensis 
A novel approach was used to identify proteins associated with the response of animals 
to F. tularensis infection. The usual method of studying the immune response in animals 
towards a lethally infectious agent is to immunize a subject with killed whole cell components. 
Attenuated, or genetically modified strains which are compromised in their ability to elicit 
infection, can also be used, but the nature of the F. tularensis LVS attenuation is not known 
(Ellis, et al, 2002). With the LD 5 0 of F. tularensis LVS for some strains of mice approaching 
a single organism (Elkins et al, 2003), animals challenged with infection by whole cell 
pathogens may perish before immune sera can be collected. 
Recent work by Kieffer et al (2003) has suggested that the use of F. tularensis LPS 
can protect against challenge by either F. tularensis LVS or F. novicida. However, this 
protection was gained only three days post immunization, far before the development of 
humoral or cellular immunity. Regardless, the protection appeared to be long term. The notion 
that perhaps polysaccharide could be used to prime the immune response against future 
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infection was entertained. 
It was noted that F. tularensis antisera cross reacts with Brucella spp. (Francis, 1926; 
Behan, et al., 1982). Our results indicate that when balb/c mice were immunized with an 
experimental DND B. suis 1193 OPS/protein vaccine, 60% were protected when challenged 
with 10 LD 5 0 of F. tularensis LVS (12/20 survival), suggesting a method of obtaining anti F. 
tularensis serum against the infection process, not just against killed cells. Sera collected from 
these Brucella-primed F. tularensis challenged mice were used in all subsequent experiments. 
The sera appeared to contain antibodies which were useful in protecting animals against live F. 
tularensis LVS infection (Table 1 and Table 2). Identification of a component involved in the 
live infection may be key to providing protection against disease. Identification of an 
immunologically significant protein involved in the live disease process may lead to the 
development of a new vaccine. Such a protein candidate was identified with the 
aforementioned serum: a 52 kDa component. 
Amicon pressure filtration with a 30 kDa molecular weight cutoff membrane (MWCO) 
was used to concentrate a 52 kDa component from F. tularensis LVS liquid culture 
supernatants. This component was identified using murine anti F. tularensis sera, prepared 
from the Brucella primed F. tularensis challenged mice (Figure 1 and Figure 3), but not with 
serum preparred using killed whole cells. While previous researchers have identified 
immunologically sensitive 17 kDa, 23 kDa and 60 kDa components, this 52 kDa component 
has not been previously described. This 52 kDa component may represent a potential 
subcellular vaccine candidate for F. tularensis. 
11 
The 52 kDa component appeared in all F. tularensis cell lysates (Figure 1). It did not 
appear to be up or down regulated during subculturing (with standardization of protein loading), 
nor did it appear to be differentially expressed with increasing culture time. The 52 kDa 
component may be extracellular or intracellular in nature. Although the amount of extacellular 
material likely increased with increased culture time, the increase was likely due to a greater 
amount of cell lysis; i.e., total protein released by lysis of the cells increased as the 52 kDa 
component increased in concentration (Figure 5). 
Periodically, the 52 kDa component appeared as a doublet of approximately 51 kDa 
and 52 kDa, respectively (Figure 1 and Figure 4). We hypothesize that upon subculturing the 
51/52 kDa component may be: 1) proteolytically processed in response to external influences 
thereby decreasing its molecular weight and/or 2) glycosylated with a specific carbohydrate 
sequence, thereby increasing its molecular weight. This hypothesized modification has unknown 
significance to the state of the culture or to the activity of the component. 
Previous work has been unsuccessful in identifying new immunologically active cellular 
components. Of note, was a 17 kDa component which has been previously identified as a cell 
membrane component by Sjostedt et al. (1991), a 23 kDa component that is an apparent heat 
shock protein (Golovliov et al. 1997) as well as a 60 kDa chaperonin protein. The 17 kDa 
component is active in T-cell proliferation assays, suggesting that it may be a candidate for 
future subcellular vaccines. Our work suggests that there are other components within the F. 
tularensis LVS cell lysate that are capable of eliciting a NO. While the 52 kDa component 
was detected in all fractions able to elicit NO, it is possible that it may be a key component in 
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provoking a cytokine burst. With the understanding that a cytokine burst is necessary to 
control F. tularensis infection, this induction shows that this component, or others like it may 
play an integral part in protecting the host against infection. 
Periodate-based stains used to detect carbohydrates attached to the 52 kDa were 
inconclusive. Staining of a Mono-Q 10/10 fractionated F. tularensis LVS cell lysate resulted 
in the identification of numerous components (Figure 7), including a 17 kDa component which 
is proven to be extracellular. The 52 kDa component did not stain in these experiments 
suggesting that there was no carbohydrate associated with it suggesting an intracellular nature to 
the component. 
F. tularensis may harbor a plasmid that encodes toxins. This plasmid might be released 
into the media, or differentially expressed when the bacterium is stressed. However, when the 
bacteria were exposed to the stressful condition of growth on synthetic media (CSM) and 
serially subcultured no plasmids were detected. 
Enzymatic digestion of F. tularensis LVS liquid culture supernatant was carried out to 
characterize the 52 kDa component. Lipase, RNAase and lysozyme had no effect on detection 
of the 52 kDa component by Brucella-primed anti F. tularensis antiserum suggesting that the 
52 kDa component lacks an RNA, lipid or N-acetylmuramic acid moiety. A general protease 
also was used to determine if the 52 kDa component was a protein. Proteinase-K, which 
cleaves peptide bonds, effectively eliminated all antibody-based detection of the 52 kDa 
component, making it apparent that the 52 kDa component is mostly protein in nature. 
Treatment of the 52 kDa protein with DNAase lowered its molecular weight from 52 
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kDa to 37 kDa (Figure 8). This shift in molecular weight following treatment by DNAase 
suggests that the 52 kDa protein may be a nucleoprotein. Autolysis may have occurred within 
the bacterial culture, releasing this component into the solution. Likewise, during infection, 
destruction of the bacteria takes place as the immune system protects the host, thus allowing the 
component to be displayed to the host's cellular immune system. Such a component may only 
be detectable as a result of a live challenge. Given the pathogen's intracellular nature and the 
innate ability of the host to fight infection, protection against such an intracellular component 
may be useful in conferring long term immunity. 
4.2 Cytotoxicity of F. tularensis 
It has been noted that sterile F. tularensis LVS supernatants grown in liquid CSM are 
able to kill Balb/c mice (Cherwonogrodzky, unpublished data). Because screening in animals is 
expensive, a tissue culture model was adopted to investigate this property further. Macrophages 
are the primary defense against cellular pathogens. F. tularensiss is an intracellular pathogen 
that is capable of surviving within macrophages and evading the immune response. A murine 
macrophage cell line, J774.1a, was chosen to mimic macrophage infections in culture and act as 
a model for F. tularensis induced cell cytotoxicity. Cell viability was assayed using 
AlamarBlue, a vital dye which only is taken up by viable cells. 
Macrophages were treated with a KC1 salt gradient to mimic the range of 
concentrations used in Chamberlain's synthetic media and F. tularensis cell lysate FPLC 
fractions used in our experiments. There was no increase in cellular death associated with the 
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salt concentrations tested. This indicated that the 111 A. 1 murine macrophages remained fully 
viable within the range of salt concentrations present in the treatment solutions and any 
cytotoxic effects observed were due to other components in solution. Cytotoxic effects were 
not observed in the J774.1 cultures treated with cell fractions prepared using FPLC. However, 
nitric oxide was induced by a few of these fractions without induction of cell death. Cytotoxic 
effects were observed when cells were treated with high (>1.00 mg/mL) concentrations of F. 
tularensis LVS cell lysate. This suggests that there are components within F. tularensis LVS 
which are capable of inducing cell death. Apoptosis has previously been identified as an 
important factor in fighting infection (Lai et al, 2001); defense against such intracellular 
pathogens may include triggering the apoptotic pathway (Kauffman, 1999). 
4.3 Cytokine and Immune Response 
The immune response against intracellular pathogens is a complex one and the 
relationship between the cytokine response and cellular action appears to be key to 
understanding the pathogenesis of disease. Research has pointed to a duplex role for T-cells 
and B-cells in the pathogenesis of disease. Work has shown that T-cell deficient mice can 
control infection, but not successfully clear disease. This is almost expected, given the 
intracellular nature of the bacterium. Interestingly, B-cell deficient mice can also control 
infection as well as successfully clear the disease, but are impaired in their ability to clear a 
second infection (Elkins et al. 2003). This impairment of long term immunity is consistent with 
the loss of B-cell function and again points to the requirement of functioning T-cells for defense 
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against F. tularensis. It appears that the role of B-cells in controlling infection is somewhat 
mixed and that T-cells may be the determining factor in preventing outright disease. To support 
this notion, Poquet et al. (1998) documented the expansion of a particular class of T-cells in 
response to F. tularensis infection. This increase in T-cell number occurred within 1-3 weeks 
post infection and appeared related to the presence of phospho-antigens. Such an expansion 
indicates the requirement for intact T-cell function in the long-term defense against Francisella. 
The cytokine response to infection is complex and is largely not understood. Research 
has indicated that mice deficient in the ability to produce NO or IFN-y are exquisitely sensitive 
to F. tularensis infection (Elkins et al. 2003). But it has also been noted that the LPS from F. 
tularensis does not induce either NO or IFN-y, pointing to the importance such cytokines have 
in bacterial defense (Kieffer, et al, 2003). In our study, we show that NO is produced by 
J774.1 macrophages after exposure to F. tularensis LVS cell lysates for 24h. Production of 
NO by murine macrophages in response to F. tularensis non-LPS components has not been 
demonstrated previously. With the importance that such cytokines have in the defense against 
Francisella, identifying an inducer of the cytokine burst is key to boosting immune reaction to 
disease. We showed that NO production increased when concentrations of F. tularensis LVS 
cell lysate was increased (Figure 18). At high concentrations of cell lysate, a cytotoxic effect 
resulting in the death of exposed macrophages was noticed which caused a marked decrease in 
NO production (Figures 17, 18). These results support the notion that NO production by 
macrophages is important to the development of an immune response to F. tularensis and that 
our novel 52 kDa component may be capable of inducing such a cytokine burst. 
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However, not all fractions from a Mono-Q fractionated F. tularensis LVS cell lysate 
were able to induce NO production in J774.1 cells. The highest concentration of NO was 
induced with Fraction 24 of the extract (Figure 19), indicating that a limited number of cell 
constituents are involved in the induction of NO. Fraction 24 contained a high concentration of 
protein in solution and included immunogenic components with molecular weights of 17 kDa, 
34 kDa and 52 kDa. We believe that these components are important to the host response 
against F. tularensis. 
4.4 Development of a Tularemia vaccine 
In this study, we demonstrated that CDl mice are susceptible to F. tularensis 
infection. Three vaccination scenarios for CDl mice were tested: 1) the ability of F. tularensis 
LVS cellular components to evoke cross protection against a F. tularensis LVS challenge 2) 
ability of Brucella spp. OPS components to evoke cross protection against a F. tularensis 
LVS infection and 3) the ability of Brucella spp. OPS-based vaccine mixed with various F. 
tularensis components to provide immunity to F. tularensis infection. 
Components in the F. tularensis LVS cell lysate appeared to possess components 
which were able to prime the murine immune system sufficiently to infer 100% protection 
against 250 LD 5 0 of F. tularensis LVS. Lower protection rates were observed with the 52 
kDa enriched fraction (#29) (Figure 16, Table 1) and the >30 kDa concentrate, 40% and 20% 
respectively. This suggests that mixtures of protein and cellular constituents may be required to 
induce complete protection against bacterial infection by F. tularensis. 
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Polysaccharide (OPS) is a powerful immunomodulator and can be used as a 
vaccine against various disease bacteria, such as Meningococcus, Streptococcus and, to some 
extent, Francisella (Kieffer, et al., 2003). It has been noted that the OPS of F. tularensis 
LVS is not an effective immunomodulator and has been described as having only 1/1000 the 
activity of E. coli polysaccharide. It has also been noted that Brucella spp. has cross reactivity 
with Francisella spp. Using this knowledge, we hypothesized that it might be useful to 'prime' 
the murine immune system with Brucella OPS prior to F. tularensis infection. 
In these studies we demonstrate that Brucella OPS primed, F. tularensis LVS 
challenged murine sera are cross reactive with proteins from F. tularensis LVS extracts. By 
itself, Brucella spp. OPS inferred very little protection against a 250 LD 5 0 F. tularensis LVS 
challenge (table 1). Only B. abortus 1119-3 OPS provided protection (40%) while B. 
melitensis 16M and B. suis 156 OPS did not provide any protection against a F. tularensis 
LVS challenge. However, when B. suis 145 OPS was combined with various F. tularensis 
LVS substituents, some level of protection was observed. B. suis OPS combined with F. 
tularensis LVS cell lysate showed no increase in protection as one cannot have higher than 
100% protection. When B. suis OPS was combined with a 52 kDa enriched fraction (#29) 
(Figure 16, Table 1), an increase in protection from 20% to 40% was observed. While 
statistically insignificant, this may suggest that B. suis OPS is capable of boosting the immune 
response to F. tularensis. Similarly, when B. suis OPS was combined with >30 kDa Amicon 
concentrated F. tularensis components, a 100% protection against a 250 LD 5 0 F. tularensis 
LVS challenge was achieved (Figure 16, Table 1). 
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While B. suis OPS is not an effective vaccine against 250 LD 5 0 of F. tularensis LVS, it 
is able to prime the murine immune system enough to allow it to respond to various F. 
tularensis LVS cellular components in a vaccination trial. These results indicate that there are 
fractions of F. tularensis LVS which would be good candidates for vaccines. 
4.5 Conclusion 
Our work has contributed to many of these research areas. With the identification of a 
novel 52 kDa component using a method which requires complete resolution of infection, our 
component constitutes an immunologicaly significant protein. The characterization suggests that 
this 52 kDa component is protein in nature, is non-glycosylated and may be intracellular with a 
partial DNA component. We have also shown that the protein invokes a basic cytokine 
response, something key to the defense against disease. Our vaccine work, albeit preliminary, 
suggests a role for the 52 kDa protein in protecting against F. tularensis infection. 
If the FDA approves the live-attenuated F. tularensis LVS for general use, the 52 kDa 
component may have potential to be used as a 'quality control' measure in vaccine 
preparations. Lastly, out detection of this component appeared to be very specific, with no 
cross reactivity occurring to either Brucella antisera, or with sera prepared using killed whole-
cell F. tularensis. This protein may therefore be useful in early detection systems similar to 
those that employ the 17 kDa TUL4 lipoprotein. 
There remains a great deal of work to be completed to fully characterize the 52 kDa 
protein. Our work suggests a role for this protein in infection as well as immunity and may 
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therefore be a powerful tool in further Francisella research. With the constant threat of 
bioterrorism; we believe it prudent that such proteins be characterized and investigated as 
thoroughly as possible. There is a great deal of potential present in this 52 kDa F. tularensiss 
antigen. 
4.6 Future Work 
Francisella is a difficult organism to work with. There remains many unknowns with 
respect to the pathogenesis of disease, structure, genome as well as virulence. Some 
researchers have commented that Francisella is an 'enigma' (Titball, et al, 2003). Many 
groups around the globe are investigating various aspects of the disease process. Major 
research areas include: epidemiology, early detection, genomic sequencing, 2D gel 
electrophoresis with protein identification (encompassing the greater class of proteomics), 
identification of virulence factors, immune response characterization and finally, improvement of 
the current vaccine. 
We hope to further characterize this component. It would be prudent to repeat our 
experiments using 2D electrophoresis and attain a partial sequence for this 52 kDa protein. 
Once sequenced, we could clone this protein and gain sufficient, pure protein to perform 
immunological experiments. We might characterize further cytokine responses to this 
component, including TNFa, IFN-y, and IL-12. The interaction of this component in tissue 
culture, using T-cells and macrophages, could also be explored. 
As a product, the 52 kDa protein component has potential in a number of areas. It 
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may be useful as a sub-cellular vaccine to F. tularensis. Further testing with virulent strains is 
necessary to properly characterize the protein/host interaction. 
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Appendix A 
Fixer: 
25% (v/v) isopropanol 
7% (v/v) acetic acid 
Oxidizer 
0.7% Periodic acid 
40% ethanol (or isopropanol) 
5% acetic acid 
(Hitchcock and Brown (1983) Journal of Bacteriology 154:269-277) 
Silver Reagent 
1:10 dilution of Bio-Rad silver staining reagent with 3X distilled water 
Developer 
1.6% (w/v) Bio-Rad powder developer 
Stop Bath 
5% (v/v) acetic acid 
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LPS Silver Stain 
A six step silver staining method was utilized to preferentially stain LPS components present on 
the polyacrylamide gel. This method was modified from the standard Bio-Rad protocol. A 
periodic acid oxidizer was utilized in place of the supplied dichromate oxidizer. 
Step Action Time 
1 Fixer 2x15 min 
2 Oxidizer 5 min 
3 Wash 10 min 
4 Silver Reagent 20 min 
5 Wash 1-30 sec 
Appendix B 
Chamberlains Synthetic Media _ „ „ J
 Component mg/L 
(CSM) 
L-arginine (free base) 400 
Add all components to 90% volume L-Aspartic Acid 400 
of triple distilled water except L-
Cysteine-HCl. Raise pH to 10 with L - C y s t e i n e " H C 1 2 0 0 
1 .ON NaOH to bring undissolved L-ffistidine (free base) 200 
substituents into solution. Bring pH t o ^
 I s o l e u c i n e 4 0 0 
7.4 with 1.0N HC1. Add remaining 
amino acid and bring to volume. L-Leucine 400 
Filter sterile through a 0.2um filter L-Lysine 400 
sterilization unit (Nalgene 1.0L unit). 
DL-Methionine 400 
Chamberlain RE. Evaluation of L-Proline (hydroxy-L-Proline-free) ' 2000 
Live Tularemia Vaccine Prepared
 DL-Serine 400 
in a Chemically Defined Media. 
Applied Microbiology 1965 13:232- DL-Threonine (allo-free) 2000 
235 L-Tyrosine 400 
DL-Valine 400 
Spermidine Triphosphate 40 
Thiamine-HCl 4 
DL-Calcium Panthothenate 2 
Glucose 4000 
Sodium Chloride 10000 
MgSCyH 20 135 
FeSO 4 .7H :0 2 
KH 2 P0 4 1000 
K 2HPQ 4 1000 
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Appendix C 
Component 7.5% gel 4% stacking gel 
water (triple distilled) 6.08 mL 3.7 mL 
3M Tris pH8.9 1.45 mL 0.6 mL 
40% Acrylamide (29:1 acrylamide:bisacrylamide) 1.88 mL 0.5 mL 
2% SDS (w/v) 0.5 mL 0.25 mL 
TEMED 10 uL 5 uL 
10% w/v Amonium persulfate 100 uL 50 uL 
2X Sample Buffer 
100 mM Tris-HCl, pH 6.8 
20% glycerol 
2% SDS 
200 mM DTT 
0.1% bromophenol blue 
10X running buffer 
30g Tris base 
144g glycine 
lOg SDS 
to 1.0L water 
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Conditions for polyacrylamide gel electrophoresis 
Appendix D 
Prestained Molecular Weight Standards (Bio-Rad product numbers) 
Low Range 161-0306 
High Range 161-0311 
Broad Range 161-0319 
Protein MW(kDa) Low Range High Range Broad Range 
Myosin 200 X X 
P-galactosidase 116.25 X X 
Phosphorylase b 97.4 X X X 
Bovine Serum Albumin 66.2 X X X 
Ovalbumin 45 X X X 
Carbonic Anhydrase 31 X X 
Soybean Trypsin Inhibitor 21.5 X X 
Lysozyme 14.4 X X 
Aprotinin 6.5 X 
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